• Testing for Inherited Susceptibility to Breast Cancer.
    • Robson M.
    • Hematol Oncol Clin North Am. 2023 Feb;37(1):17-31. doi: 10.1016/j.hoc.2022.08.003.
    • Review
    • The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 24. doi: 10.1080/14737167.2023.2169136. Epub ahead of print.
    • Genetic Testing for Cancer Risk and Perceived Importance of Genetic Information Among US Population by Race and Ethnicity: a Cross-sectional Study.
    • Hong YR, Yadav S, Wang R, Vadaparampil S, Bian J, George TJ, Braithwaite D.
    • J Racial Ethn Health Disparities. 2023 Jan 23. doi: 10.1007/s40615-023-01526-4. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld.
    • Ray T.
    • Precision Oncology News. 2023 Jan 23.
    • The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 13. doi: 10.1080/14737167.2023.2169135. Epub ahead of print.
    • The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study.
    • Chu DT, Vu Ngoc Suong M, Vu Thi H, Vu TD, Nguyen MH, Singh V.
    • Expert Rev Mol Diagn. 2023 Jan 12. doi: 10.1080/14737159.2023.2168190. Epub ahead of print.
    • Review
    • Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
    • Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M.
    • JCO Oncol Pract. 2023 Jan 12:OP2200638. doi: 10.1200/OP.22.00638. Epub ahead of print.
    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary
    • January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey.
    • Mechanic L, Helzlsouer K.
    • Genet Med. GenePOD. 2023 Jan 9.

    •• Original research:

    Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.

    • Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis.
    • Anaclerio F, PILENZI L, Dell'elice A, Ferrante R, Gildetti S, Ferlito LM, Marinelli C, Calabrese G, Stuppia L, Antonucci I.
    • Front Genet. 2023 Jan 4;12:1060504. doi: 10.3389/fgene.2023.1060504.
    • Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants.
    • Subaşıoğlu A, Güç ZG, Gür EÖ, Tekindal MA, Atahan MK.
    • Eur J Breast Health. 2023 Jan 1;19(1):55-69. doi: 10.4274/ejbh.galenos.2022.2022-7-2.
    • Development of a comprehensive approach to adult hereditary cancer testing in Ontario.
    • Bell KA, Kim R, Aronson M, Gillies B, Ali Awan A, Chun K, Hart J, Healey R, Kim L, Klaric G, Panabaker K, Sabatini PJB, Sadikovic B, Selvarajah S, Smith AC, Stockley TL, Vaags AK, Eisen A, Pollett A, Feilotter H.
    • J Med Genet. 2022 Dec 23:jmg-2022-108945. doi: 10.1136/jmg-2022-108945. Epub ahead of print.
    • Oncogenetica [Oncogenetics].
    • Suerink M, Bleiker EMA, Nielsen M, Houwink EJF, Baas JM, Ausems MGEM.
    • Ned Tijdschr Geneeskd. 2022 Dec 22;167:D6958. Dutch.
    • [Article in Dutch]
    • Parent-of-origin detection and chromosome-scale haplotyping using long-read DNA methylation sequencing and Strand-seq.
    • Akbari V, Hanlon VCT, O’Neill K, Lefebvre L, Schrader KA, Lansdorp PM, Jones SJM.
    • Cell Genom. 2022 Dec 21. doi: 10.1016/j.xgen.2022.100233. Epub ahead of print.

    •• Research news: Genetic Test Identifies Parental Source of Cancer Variant. (Medscape Oncology)

    • Informational needs of individuals from BRCA-harboring families: a systematic review and content analysis.
    • Park SY, Kim Y, Kim S, Katapodi MC.
    • Genet Med. 2022 Dec 18:S1098-3600(22)01068-1. doi: 10.1016/j.gim.2022.100001. Epub ahead of print.
    • Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
    • Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S, Tomer A, Levy-Lahad E, Lahad A.
    • Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113.
    • Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system.
    • Grant P, Cook CB, Langlois S, Nuk J, Mung S, Zhang Q; GenCOUNSEL Study, Lynd LD, Austin J, Elliott AM.
    • Clin Genet. 2022 Dec 11. doi: 10.1111/cge.14276. Epub ahead of print.
    • RE: Heterozygous BRCA1/BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
    • Evans DG, Woodward ER.
    • J Natl Cancer Inst. 2022 Dec 10:djac223. doi: 10.1093/jnci/djac223. Epub ahead of print.

    •• Letter, Reply:

    Reply to Evans and Woodward.

    •• Original research:

    Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.

    • Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
    • Macklin-Mantia SK, Clift KE, Maimone S, Hodge DO, Riegert-Johnson D, Hines SL.
    • J Genet Couns. 2022 Dec 7. doi: 10.1002/jgc4.1665. Epub ahead of print.
    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.
    • Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
    • Sokolova A, Johnstone KJ, McCart Reed AE, Simpson PT, Lakhani SR.
    • Histopathology. 2022 Dec 5. doi: 10.1111/his.14808. Epub ahead of print.
    • Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.
    • Tiner JC, Mechanic LE, Gallicchio L, Gillanders EM, Helzlsouer KJ.
    • Genet Med. 2022 Dec;24(12):2526-2534. doi: 10.1016/j.gim.2022.08.023. Epub 2022 Sep 22.

    •• Podcast: January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey. (Genetics in Medicine GenePOD)

    • Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019.
    • Winchar K, Lambert P, McManus KJ, Chodirker B, Kean S, Serfas K, Decker K, Nachtigal MW, Altman AD.
    • Curr Oncol. 2022 Nov 30;29(12):9365-9376. doi: 10.3390/curroncol29120735.
    • Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders.
    • Carrasco E, López-Fernández A, Codina-Sola M, Valenzuela I, Cueto-González AM, Villacampa G, Navarro V, Torres-Esquius S, Palau D, Cruellas M, Torres M, Perez-Dueñas B, Abulí A, Diez O, Sábado-Álvarez C, García-Arumí E, Tizzano EF, Moreno L, Balmaña J.
    • J Med Genet. 2022 Nov 29:jmg-2022-108929. doi: 10.1136/jmg-2022-108929. Epub ahead of print.
    • Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
    • Evans DG, Sithambaram S, van Veen EM, Burghel GJ, Schlecht H, Harkness EF, Byers H, Ellingford JM, Gandhi A, Howell SJ, Howell A, Forde C, Lalloo F, Newman WG, Smith MJ, Woodward ER.
    • J Med Genet. 2022 Nov 28:jmg-2022-108790. doi: 10.1136/jmg-2022-108790. Epub ahead of print.
    • Halo Diagnostics, Ikonopedia Partner to Provide Genetic Testing for Breast Cancer.
    • [No author given]
    • Precision Oncology News. 2022 Nov 28.
    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
    • Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
    • Kratz CP, Smirnov D, Autry R, Jäger N, Waszak SM, Großhennig A, Berutti R, Wendorff M, Hainaut P, Pfister SM, Prokisch H, Ripperger T, Malkin D.
    • J Natl Cancer Inst. 2022 Nov 14;114(11):1523-1532. doi: 10.1093/jnci/djac151.

    •• Letter, Commentary:

    RE: Heterozygous BRCA1/BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.

    •• Letter, Reply:

    Reply to Evans and Woodward.

    • Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer.
    • Hughes BN, Jorgensen KA, Cummings S, Morah D, Krause K, Rauh-Hain JA, Herzog TJ.
    • Int J Gynecol Cancer. 2022 Nov 11:ijgc-2022-003913. doi: 10.1136/ijgc-2022-003913. Epub ahead of print.
    • Review
    • Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer.
    • Hollasch M, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing.
    • Rosa K, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Dr. Shore on the Importance of Genetic Testing in Prostate Cancer.
    • Shore N.
    • OncLive. OncLive TV. 2022 Nov 11.
    • Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in Oncology for the public sector.
    • Van Der Merwe NC, Ntaita KS, Stofberg H, Combrink HM, Oosthuizen J, Kotze MJ.
    • Front Oncol. 2022 Nov 8;12:938561. doi: 10.3389/fonc.2022.938561.
    • Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk.
    • Guan Y, Pathak S, Ballard D, Veluswamy JK, McCullough LE, McBride CM, Gornick MC.
    • Front Public Health. 2022 Nov 8;10:984926. doi: 10.3389/fpubh.2022.984926.
    • Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
    • Li Y, Chen L, Lv J, Chen X, Zeng B, Chen M, Guo W, Lin Y, Yu L, Hou J, Li J, Zhou P, Zhang W, Li S, Jin X, Cai W, Zhang K, Huang Y, Wang C, Fu F.
    • BMC Cancer. 2022 Nov 2;22(1):1125. doi: 10.1186/s12885-022-10160-y.
    • Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    • Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
    • Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.
    • From the patient to the population: Use of genomics for population screening.
    • Mighton C, Shickh S, Aguda V, Krishnapillai S, Adi-Wauran E, Bombard Y.
    • Front Genet. 2022 Oct 24;13:893832. doi: 10.3389/fgene.2022.893832.
    • Overview on population screening for carriers with germline BRCA mutation in China.
    • Lei H, Zhang M, Zhang L, Hemminki K, Wang X, Chen T.
    • Front Oncol. 2022 Oct 24;12:1002360. doi: 10.3389/fonc.2022.1002360.
    • An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study.
    • Coffin T, Bowen D, Swisher E, Lu K, Rayes N, Norquist B, Blank S, Levine D, Bakkum-Gamez J, Fleming G, Olopade O, D'Andrea A, Nebgen D, Peterson C, Munsell M, Gavin K, Lechner R, Crase J, Polinsky D, Romero I.
    • JMIR Form Res. 2022 Oct 17;6(10):e34055. doi: 10.2196/34055.
    • Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania.
    • Felbor U, Bülow R, Schmutzler RK, Rath M.
    • Healthcare (Basel). 2022 Oct 13;10(10):2021. doi: 10.3390/healthcare10102021.
    • Genetic Testing Challenges in Oncology: Missed Variant Update Delays Li-Fraumeni Diagnosis.
    • Ray T.
    • Precision Oncology News. 2022 Oct 12.

    Special article:

    Is there a duty to reinterpret genetic data? The ethical dimensions.

    • Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors.
    • Conley CC, Rivera Rivera JN, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Ricker C, Quinn GP, Soliman H, Vadaparampil ST.
    • Transl Behav Med. 2022 Oct 7;12(9):900-908. doi: 10.1093/tbm/ibac031.
    • Population genomic screening: Ethical considerations to guide age at implementation.
    • Spencer SJ, Fullerton SM.
    • Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648.
    • Genetic testing for patients at risk of hereditary breast and ovarian cancer.
    • DeTroye A, Gabbett K, Yi C, Judice M, Luu V, Nelson B, Gregory T.
    • JAAPA. 2022 Oct 1;35(10):48-52. doi: 10.1097/01.JAA.0000873796.81961.da.
    • Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.
    • Ip E, Young AL, Scheinberg T, Harrison M, Beale P, Goodwin A.
    • Asia Pac J Clin Oncol. 2022 Oct;18(5):e414-e419. doi: 10.1111/ajco.13741. Epub 2022 Jan 30.
    • Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges.
    • Charron M, Kaiser B, Dauge A, Gallois H, Lapointe J, Dorval M, Nabi H, Joly Y.
    • Crit Rev Oncol Hematol. 2022 Oct;178:103797. doi: 10.1016/j.critrevonc.2022.103797. Epub 2022 Aug 27.
    • Review
    • BRCA1/2 Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes.
    • Harriman JW, Espinel WF, Vagher J, Gammon A.
    • JCO Precis Oncol. 2022 Oct;6:e2100375. doi: 10.1200/PO.21.00375.
    • Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low-to-middle income Asian country.
    • Lee YQ, Yoon SY, Hassan T, Padmanabhan H, Yip CH, Keng WT, Thong MK, Ahmad Annuar MA, Mohd Taib NA, Teo SH.
    • J Genet Couns. 2022 Oct;31(5):1080-1089. doi: 10.1002/jgc4.1579. Epub 2022 Apr 28.
    • Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment.
    • Nehoray B, Slavin TP, Sun CL, Hurley K, King E, Tsang KK, Cervantes A, Mokhnatkin JV, Sand S, Mejia R, Reb A, Samimi G, Gray S, Blazer KR, Weitzel JN.
    • J Genet Couns. 2022 Oct;31(5):1164-1172. doi: 10.1002/jgc4.1587. Epub 2022 May 26.
    • Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients.
    • Butow P, Napier C, Campbell R, Bartley N, Best M, Ballinger ML.
    • Patient Educ Couns. 2022 Oct;105(10):3110-3115. doi: 10.1016/j.pec.2022.06.009. Epub 2022 Jun 16.
    • Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome.
    • Vicente R, Alpuim Costa D, Vitorino M, Mendes AD, Santos C, Fontes-Sousa M.
    • Cancers (Basel). 2022 Sep 28;14(19):4717. doi: 10.3390/cancers14194717.
    • Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    • Ohneda K, Hamanaka Y, Kawame H, Fuse N, Nagami F, Suzuki Y, Yamaguchi-Kabata Y, Shimada M, Masamune A, Aoki Y, Ishida T, Yamamoto M.
    • Breast Cancer. 2022 Sep 26. doi: 10.1007/s12282-022-01404-7. Epub ahead of print.
    • Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.
    • Coffin T, Bowen D, Lu K, Swisher EM, Rayes N, Norquist B, Blank SV, Levine DA, Bakkum-Gamez JN, Fleming GF, I Olopade O, Romero I, D'Andrea A, Nebgen DR, Peterson C, Munsell MF, Gavin K, Crase J, Polinsky D, Lechner R.
    • JMIR Form Res. 2022 Sep 26;6(9):e35035. doi: 10.2196/35035.

    Identifier: NCT02993068: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible). (ClinicalTrials.gov)

    • Genetic Tests Create Treatment Opportunities and Confusion for Breast Cancer Patients.
    • Andrews M.
    • KHN [Kaiser Health News]. 2022 Sep 21.

    Press: Genetic Tests Create Treatment Opportunities and Confusion for Breast Cancer Patients. (Medscape)

    • Implementation and outcome evaluations of a multi-site improvement program in cancer genetics.
    • Bednar EM, Harper B, Walsh MT Jr, Rechis R, Bilbao M, Carr RL, Eppolito AL, Goedde T, Levin B, Mattie K, Morman NA, Rath K, Russ P, Siettmann JM, Warshal D, Wise E, Yobbi C, Lu KH.
    • J Genet Couns. 2022 Sep 19. doi: 10.1002/jgc4.1633. Epub ahead of print.
    • Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.
    • Esplin ED, Nielsen SM, Bristow SL, Garber JE, Hampel H, Rana HQ, Samadder NJ, Shore ND, Nussbaum RL.
    • JCO Precis Oncol. 2022 Sep [2022 Sep 15];6:e2100516. doi: 10.1200/PO.21.00516.
    • Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.
    • Llorin H, Graf M, Chun N, Ford J.
    • Cancer Genet. 2022 Sep 6;268-269:22-27. doi: 10.1016/j.cancergen.2022.09.001. Epub ahead of print.
    • What can we learn from more than 1000 Brazilian patients at risk of hereditary cancer?
    • Leite ACR, Suzuki DA, Pereira AAL, Machado NP, Barroso-Sousa R, Correa TS, Moura FC, Morbeck IAP, Gumz BP, Faria LDBB, Fernandes GDS, Sandoval RL.
    • Front Oncol. 2022 Sep 5;12:963910. doi: 10.3389/fonc.2022.963910.
    • Screening for Individuals at Risk for Hereditary Breast and Ovarian Cancer: A Statewide Initiative, Georgia, 2012-2020.
    • Veitinger JK, Kerber AS, Gabram-Mendola SGA, Liu Y, Durham LM, Durrence D, Berzen AK, Shin JY, Snyder C, Bellcross CA, Guan Y.
    • Am J Public Health. 2022 Sep;112(9):1249-1252. doi: 10.2105/AJPH.2022.306932. Epub 2022 Jul 21.
    • Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
    • Linfield DT, Rothberg MB, Pfoh ER, Noss R, Cassard L, Powers JC, Lipold L, Martinez KA.
    • Breast Cancer Res Treat. 2022 Sep;195(2):153-160. doi: 10.1007/s10549-022-06523-5. Epub 2022 Jul 16.
    • Uptake of genetic counseling and testing in a clinic-based population of women with breast cancer.
    • Wehbe A, Manning M, Assad H, Purrington KS, Simon MS.
    • Cancer Med. 2022 Sep;11(17):3304-3311. doi: 10.1002/cam4.4684. Epub 2022 Mar 23.
    • Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    • Levine MD, Barrington DA, Hampel H, Goodfellow PJ, Cohn DE.
    • Gynecol Oncol. 2022 Sep;166(3):538-542. doi: 10.1016/j.ygyno.2022.07.016. Epub 2022 Jul 21.
    • Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer.
    • Gray SW, Ottesen RA, Currey M, Cristea M, Nikowitz J, Shehayeb S, Lozano V, Hom J, Kilburn J, Lopez LN, Wing S, Sosa E, Shen J, Morris M, Dilsizian B, Joseph T, Shen J, Adeimy C, Phillips T, Bahadini B, Niland JC.
    • JCO Clin Cancer Inform. 2022 Sep;6:e2200034. doi: 10.1200/CCI.22.00034.
    • Call for action: expanding global access to hereditary cancer genetic testing.
    • Bychkovsky B, Rana HQ, Ademuyiwa F, Plichta J, Anderson K, Nogueira-Rodrigues A, Santa-Maria CA, Coffman LG, Marquez C, Das A, Taghian A, Koeller DR, Sandoval RL, Park BH, Dizon DS.
    • Lancet Oncol. 2022 Sep;23(9):1124-1126. doi: 10.1016/S1470-2045(22)00378-3.
    • Commentary
    • Array genotyping as diagnostic approach in medical genetics.
    • Witsch-Baumgartner M, Schwaninger G, Schnaiter S, Kollmann F, Burkhard S, Gröbner R, Mühlegger B, Schamschula E, Kirchmeier P, Zschocke J.
    • Mol Genet Genomic Med. 2022 Sep;10(9):e2016. doi: 10.1002/mgg3.2016. Epub 2022 Aug 1.
    • Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
    • Peters MLB, Eckel A, Lietz A, Seguin C, Mueller P, Hur C, Pandharipande PV.
    • Pancreatology. 2022 Sep;22(6):760-769. doi: 10.1016/j.pan.2022.05.003. Epub 2022 May 31.
    • Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
    • Xu J, Resurreccion WK, Shi Z, Wei J, Wang CH, Zheng SL, Hulick PJ, Ross AE, Pavlovich CP, Helfand BT, Isaacs WB.
    • Prostate Cancer Prostatic Dis. 2022 Sep;25(3):422-430. doi: 10.1038/s41391-021-00458-6. Epub 2022 Mar 28.
    • Review
    • Role of genetic testing in hepatic, pancreatic, and biliary cancers.
    • Hewitt DB, Aziz H, Brown ZJ, Pawlik TM.
    • Surg Oncol. 2022 Sep;44:101844. doi: 10.1016/j.suronc.2022.101844. Epub 2022 Sep 5.
    • Review
    • Population based genetic testing for cancer susceptibility genes: quo vadis.
    • Manchanda R, Sideris M.
    • BJOG. 2022 Aug 26. doi: 10.1111/1471-0528.17283. Epub ahead of print.
    • Commentary
    • BRCA testing on buccal swab to improve access to healthcare and cancer prevention: a performance evaluation.
    • De Paolis E, Perrucci A, Marchetti C, Pietragalla A, Scambia G, Urbani A, Fagotti A, Minucci A.
    • Int J Gynecol Cancer. 2022 Aug 26:ijgc-2022-003718. doi: 10.1136/ijgc-2022-003718. Epub ahead of print.
    • Estimating lifetime risk for breast cancer as a screening tool for identifying those who would benefit from additional services among women utilizing mobile mammography.
    • Wetmore JB, Otarola L, Paulino LJ, Henry BR, Levine AF, Kone D, Ulloa J, Jandorf L, Margolies L, Vang S.
    • J Cancer Policy. 2022 Aug 19:100354. doi: 10.1016/j.jcpo.2022.100354. Epub ahead of print.
    • Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
    • Smallwood KG, Crockett S, Huang V, Cullimore V, Davies J, Satti G, Phillips A.
    • J Obstet Gynaecol. 2022 Aug 18:1-7. doi: 10.1080/01443615.2022.2111253. Epub ahead of print.
    • Dana-Farber Educating Black, Latinx Patients Hoping to Boost Pancreatic Cancer Genetic Risk Testing.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2022 Aug 18.
    • News
    • JSCREEN and K.I.C.K Partner to Kick Cancer with Genetic Testing.
    • Kickel Hernandez K.
    • FORCE. Blog. 2022 Aug 16.
    • I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.
    • Wilfond BS.
    • J Pediatr. 2022 Aug 16:S0022-3476(22)00728-4. doi: 10.1016/j.jpeds.2022.08.019. Epub ahead of print.
    • Commentary

    Original research:

    Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.

    • Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.
    • Ceyhan-Birsoy O, Jayakumaran G, Kemel Y, Misyura M, Aypar U, Jairam S, Yang C, Li Y, Mehta N, Maio A, Arnold A, Salo-Mullen E, Sheehan M, Syed A, Walsh M, Carlo M, Robson M, Offit K, Ladanyi M, Reis-Filho JS, Stadler ZK, Zhang L, Latham A, Zehir A, Mandelker D.
    • Genome Med. 2022 Aug 15;14(1):92. doi: 10.1186/s13073-022-01101-2.
    • Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical center.
    • Finn CM, McCormick S, Peterson D, Niendorf KB, Rodgers LH.
    • J Genet Couns. 2022 Aug 8. doi: 10.1002/jgc4.1624. Epub ahead of print.
    • A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.
    • Hughes KS, Yin K.
    • Ann Surg Oncol. 2022 Aug;29(8):4667-4669. doi: 10.1245/s10434-022-11860-2. Epub 2022 May 12.

    Original research:

    Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.

    • Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation.
    • Menko FH, Monkhorst K, Hogervorst FBL, Rosenberg EH, Adank M, Ruijs MWG, Bleiker EMA, Sonke GS, Russell NS, Oldenburg HSA, van der Kolk LE.
    • Crit Rev Oncol Hematol. 2022 Aug;176:103642. doi: 10.1016/j.critrevonc.2022.103642. Epub 2022 Mar 5.
    • Decision thresholds with genetic testing.
    • Felder S.
    • Eur J Health Econ. 2022 Aug;23(6):1071-1078. doi: 10.1007/s10198-021-01410-0. Epub 2021 Dec 2.
    • Making BRCA1 genetic test reports easier to understand through user-centered design: A randomized trial.
    • Recchia G, Lawrence ACE, Capacchione L, Freeman ALJ.
    • Genet Med. 2022 Aug;24(8):1684-1696. doi: 10.1016/j.gim.2022.04.016. Epub 2022 May 6.
    • Relatively Speaking: COVID-19’s Impact on Cancer Screenings and Genetic Counseling Services.
    • Haidle JL.
    • Inside Precision Medicine. 2022 Aug 16 [2022 Aug];9(4).
    • Relatively Speaking: COVID-19’s Impact on Cancer Screenings and Genetic Counseling Services.
    • Haidle JL.
    • Inside Precision Medicine. 2022 Aug 16 [2022 Aug];9(4).
    • Challenges and opportunities in the establishment of a hereditary breast cancer clinic at an academic medical center in a low-middle income country.
    • Ehsan L, Waheed MT, Akbar F, Siddiqui Z, Sattar AK, Kirmani S.
    • J Genet Couns. 2022 Aug;31(4):998-1002. doi: 10.1002/jgc4.1555. Epub 2022 Jan 31.
    • Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer.
    • Mansur A, Zhang F, Lu CY.
    • J Pers Med. 2022 Jul 31;12(8):1263. doi: 10.3390/jpm12081263.
    • Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.
    • Everett JN, Dettwyler SA, Jing X, Stender C, Schmitter M, Baptiste A, Chun J, Kawaler EA, Khanna LG, Gross SA, Gonda TA, Beri N, Oberstein PE, Simeone DM.
    • Cancer Med. 2022 Jul 30. doi: 10.1002/cam4.5059. Epub ahead of print.
    • Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.
    • Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA.
    • J Genet Couns. 2022 Jul 28. doi: 10.1002/jgc4.1614. Epub ahead of print.
    • Public Interest in Population Genetic Screening for Cancer Risk.
    • Roberts MC, Foss KS, Henderson GE, Powell SN, Saylor KW, Weck KE, Milko LV.
    • Front Genet. 2022 Jul 22;13:886640. doi: 10.3389/fgene.2022.886640.
    • Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting.
    • Jürgens H, Roht L, Leitsalu L, Nõukas M, Palover M, Nikopensius T, Reigo A, Kals M, Kallak K, Kütner R, Budrikas K, Kuusk S, Valvere V, Laidre P, Toome K, Rekker K, Tooming M, Ülle Murumets, Kahre T, Kruuv-Käo K, Õunap K, Padrik P, Metspalu A, Esko T, Fischer K, Tõnisson N.
    • Front Genet. 2022 Jul 22;13:881100. doi: 10.3389/fgene.2022.881100.
    • Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jul 18;12:962958. doi: 10.3389/fonc.2022.962958.

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    • Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD.
    • JAMA Netw Open. 2022 Jul 18;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092.

    Identifier: NCT03470402: Decision Support for BRCA Testing in Ethnically Diverse Women. (ClinicalTrials.gov)

    • Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.
    • Lourenção M, Simões Correa Galendi J, Galvão HCR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, de Oliveira JHC, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jul 11;12:951310. doi: 10.3389/fonc.2022.951310.
    • Women's thoughts on receiving and sharing genetic information: Considerations for genetic counseling.
    • Pfledderer CD, Gren LH, Frost CJ, Andrulis IL, Chung WK, Genkinger J, Glendon G, Hopper JL, John EM, Southey M, Terry MB, Daly MB.
    • J Genet Couns. 2022 Jul 6. doi: 10.1002/jgc4.1599. Epub ahead of print.
    • Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term secondary lifestyle behavioural outcomes.
    • Burnell M, Gaba F, Sobocan M, Desai R, Sanderson S, Loggenberg K, Gessler S, Side L, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 Jul 4. doi: 10.1111/1471-0528.17253. Epub ahead of print.
    • Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes.
    • Shah S, Cheung A, Kutka M, Sheriff M, Boussios S.
    • Int J Environ Res Public Health. 2022 Jul 1;19(13):8113. doi: 10.3390/ijerph19138113.
    • Genetic medicine is accelerating in Japan.
    • Hayashi S, Kubo M, Kaneshiro K, Kai M, Yamada M, Morisaki T, Takao Y, Shimazaki A, Shikada S, Nakamura M.
    • Breast Cancer. 2022 Jul;29(4):659-665. doi: 10.1007/s12282-022-01342-4. Epub 2022 Feb 21.
    • BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell CL, Salih Z, Woodward ER, Lalloo F, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.
    • Br J Cancer. 2022 Jul;127(1):163-167. doi: 10.1038/s41416-022-01773-y. Epub 2022 Mar 8.
    • Review
    • Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer.
    • Bokkers K, Zweemer RP, Koudijs MJ, Stehouwer S, Velthuizen ME, Bleiker EMA, Ausems MGEM.
    • Fam Cancer. 2022 Jul;21(3):295-304. doi: 10.1007/s10689-021-00277-7. Epub 2021 Oct 7.
    • Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
    • Bonelli L, Valle I, Rebora I, Ricci P, Biocchi L, Bruschi G, Parodi S, Bruzzone C, Varesco L.
    • Fam Cancer. 2022 Jul;21(3):309-318. doi: 10.1007/s10689-021-00281-x. Epub 2021 Oct 20.
    • Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
    • Dettwyler SA, Koeppe ES, Jacobs MF, Stoffel EM.
    • Fam Cancer. 2022 Jul;21(3):375-385. doi: 10.1007/s10689-021-00276-8. Epub 2021 Sep 21. Erratum in: Fam Cancer. 2021 Oct 28.
    • Polygenic risk score as a possible tool for identifying familial monogenic causes of complex diseases.
    • Lu T, Forgetta V, Richards JB, Greenwood CMT.
    • Genet Med. 2022 Jul;24(7):1545-1555. doi: 10.1016/j.gim.2022.03.022. Epub 2022 Apr 23.
    • Evaluating Costs Associated With Genetic Counseling Among Commercially Insured US Patients With Cancer From 2013 to 2019.
    • Roberson ML, Padi-Adjirackor NA, Hooker G, Pal T.
    • JAMA Health Forum. 2022 Jul 29 [eCollection 2022 Jul];3(7):e222260. doi: 10.1001/jamahealthforum.2022.2260.

    Research news: Genetic Counseling for Cancer Often Costs Patients Nothing. (Medscape Oncology)

    • Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.
    • Tindale LC, Zhantuyakova A, Lam S, Woo M, Kwon JS, Hanley GE, Knoppers B, Schrader KA, Peacock SJ, Talhouk A, Dummer T, Metcalfe K, Pashayan N, Foulkes WD, Manchanda R, Huntsman D, Stuart G, Simard J, Dawson L.
    • Curr Oncol. 2022 Jun 30;29(7):4632-4646. doi: 10.3390/curroncol29070368.
    • Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.
    • Jennings C, Wynn J, Miguel C, Levinson E, Florido ME, White M, Sands CB, Schwartz LA, Daly M, O'Toole K, Buys SS, Glendon G, Hanna D, Andrulis IL, Terry MB, Chung WK, Bradbury A.
    • J Pediatr. 2022 Jun 28:S0022-3476(22)00601-1. doi: 10.1016/j.jpeds.2022.06.027. Epub ahead of print.

    Commentary:

    I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.

    • Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.
    • Henderson V, Madrigal JM, Kendall LC, Parekh P, Newsome J, Chukwudozie IB, Comer-Hagans L, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Balay L, Maga T, Ramamonjiarivelo Z, Balthazar C, Winn R, Watson K, Odoms-Young A, Hoskins KF.
    • BMC Health Serv Res. 2022 Jun 25;22(1):826. doi: 10.1186/s12913-022-08193-x.

    Identifier: NCT04082117: Uptake of Genetic Counseling Among African American Women. (ClinicalTrials.gov)

    • What Chris Evert’s Story Can Teach the World about Genetic Testing.
    • Matloff ET.
    • FORCE. Blog. 2022 Jun 22.
    • TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    • Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study.
    • J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9.
    • Nine Myths About Men and Hereditary Cancer.
    • [No author given]
    • My Gene Counsel. Genetic Journal blog. 2022 Jun 15.
    • Not All Genetic Tests are Created Equal.
    • Cline M, Holdren J.
    • FORCE. Blog. 2022 Jun 14.
    • Literacy-adapted, electronic family history assessment for genetics referral in primary care: patient user insights from qualitative interviews.
    • Mittendorf KF, Lewis HS, Duenas DM, Eubanks DJ, Gilmore MJ, Goddard KAB, Joseph G, Kauffman TL, Kraft SA, Lindberg NM, Reyes AA, Shuster E, Syngal S, Ukaegbu C, Zepp JM, Wilfond BS, Porter KM.
    • Hered Cancer Clin Pract. 2022 Jun 10;20(1):22. doi: 10.1186/s13053-022-00231-3.

    Identifier: NCT03426878: Cancer Health Assessments Reaching Many (CHARM). (ClinicalTrials.gov)

    • African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show.
    • Anderson A.
    • GenomeWeb. Disease Areas. Cancer. 2022 Jun 7.
    • Development, Implementation and Initial Results of CDSS Recommendations for Patients at Risk of Hereditary Breast Cancer.
    • Rosa J, Tajerian M, Zin Y, Brunner M, Lopez N, Gaiera A, Butti M, Menazzi S, Chanfreau H, Luna D, Rubin L, Benitez S.
    • Stud Health Technol Inform. 2022 Jun 6;290:340-344. doi: 10.3233/SHTI220092.
    • Ovarian tumors and genetic predisposition.
    • Štellmachová J, Vrtel P, Vrtel R, Janíková M, Kolaríková K, Procházka M, Vodicka R.
    • Ceska Gynekol. 2022 Summer;87(3):211-216. English. doi: 10.48095/cccg2022211.
    • Clinical tools and counseling considerations for breast cancer risk assessment and evaluation for hereditary cancer risk.
    • Hipp LE, Hulswit BB, Milliron KJ.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:12-29. doi: 10.1016/j.bpobgyn.2022.02.001. Epub 2022 Feb 9.
    • Review
    • Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities.
    • Boere I, Lok C, Poortmans P, Koppert L, Painter R, Vd Heuvel-Eibrink MM, Amant F.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59. doi: 10.1016/j.bpobgyn.2022.05.001. Epub 2022 May 9.
    • Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.
    • Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies.
    • ESMO Open. 2022 Jun;7(3):100459. doi: 10.1016/j.esmoop.2022.100459. Epub 2022 May 19.
    • Interventions to improve delivery of cancer genetics services in the United States: A scoping review.
    • Bednar EM, Nitecki R, Krause KJ, Rauh-Hain JA.
    • Genet Med. 2022 Jun;24(6):1176-1186. doi: 10.1016/j.gim.2022.03.002. Epub 2022 Apr 7.
    • Review
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study.
    • Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16.
    • Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1/2 mutation Carriers' experience with genetic testing and counseling.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 May 2 [eCollection 2022 Jun];41:100989. doi: 10.1016/j.gore.2022.100989.
    • Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.
    • Hardy MW, Peshkin BN, Rose E, Ladd MK, Binion S, Tynan M, McBride CM, Grinzaid KA, Schwartz MD.
    • J Community Genet. 2022 Jun;13(3):281-292. doi: 10.1007/s12687-022-00590-3. Epub 2022 Apr 29.
    • Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.
    • Scott A, Mohan A, Austin S, Amini E, Raupp S, Pannecouk B, Kelley MJ, Narla G, Ramnath N.
    • JCO Oncol Pract. 2022 Jun;18(6):e966-e973. doi: 10.1200/OP.21.00693. Epub 2022 Mar 8.
    • Utilization of genetic testing: Analysis of 4,499 prior authorization requests for molecular genetic tests at four US regional health plans.
    • Bajguz D, Danylchuk NR, Czarniecki M, Selig JP, Sutphen R, Kaylor J.
    • J Genet Couns. 2022 Jun;31(3):771-780. doi: 10.1002/jgc4.1543. Epub 2021 Dec 23.
    • Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study.
    • Pace LE, Tung N, Lee YS, Hamilton JG, Gabriel C, Revette A, Raja S, Jenkins C, Braswell A, Morgan K, Levin J, Block J, Domchek SM, Nathanson K, Symecko H, Spielman K, Karlan B, Kamara D, Lester J, Offit K, Garber JE, Keating NL.
    • J Gen Intern Med. 2022 Jun;37(8):1862-1869. doi: 10.1007/s11606-021-06970-8. Epub 2021 Jun 25.

    Identifier: NCT03351803: BRCA Founder OutReach (BFOR) Study. (ClinicalTrials.gov)

    • Ethical, legal, and sociocultural challenges of genomic research in Jordan: a mixed methods study in patients with breast cancer with Jordanian-Palestinian heritage.
    • Al-Omari A, Al-Hussaini M, Zahran F, Abdel-Razeq H.
    • Lancet. 2022 Jun;399 Suppl 1:S26. doi: 10.1016/S0140-6736(22)01161-8.
    • Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    • Archer S, Fennell N, Colvin E, Laquindanum R, Mills M, Dennis R, Stutzin Donoso F, Gold R, Fan A, Downes K, Ford J, Antoniou AC, Kurian AW, Evans DG, Tischkowitz M.
    • Cancers (Basel). 2022 May 31;14(11):2716. doi: 10.3390/cancers14112716.
    • Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.
    • Acharya M, Zorn KK, Simonson ME, Bimali M, Moore GW, Peng C, Martin BC.
    • Hered Cancer Clin Pract. 2022 May 23;20(1):19. doi: 10.1186/s13053-022-00226-0.
    • UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women.
    • Kanski A.
    • Precision Oncology News. Technology. 2022 May 19.
    • News
    • Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman Study™.
    • Tone A, Boghosian T, Ross A, Baugh E, Altman AD, Dawson L, Reid F, Crawford C.
    • Curr Oncol. 2022 May 5;29(5):3318-3340. doi: 10.3390/curroncol29050271.
    • BRCA1 Variant Assessment Using a Simple Analytic Assay.
    • Kim DM, Feilotter HE, Davey SK.
    • J Appl Lab Med. 2022 May 4;7(3):674-688. doi: 10.1093/jalm/jfab163.
    • The role of genetic testing in prostate cancer screening, diagnosis, and treatment.
    • de la Calle CM, Bhanji Y, Pavlovich CP, Isaacs WB.
    • Curr Opin Oncol. 2022 May 1;34(3):212-218. doi: 10.1097/CCO.0000000000000823.
    • Review
    • Assessing Breast Cancer Risks to Improve Care for an Increased-Risk Population within Eastern North Carolina.
    • Shelton CH, Bowen C, Guenther WC, Jordan B, Boehmer LM, Weldon CB, Trosman JR, Ruiz A.
    • N C Med J. 2022 May-Jun;83(3):221-228. doi: 10.18043/ncm.83.3.221.
    • Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
    • Reisel D, Burnell M, Side L, Loggenberg K, Gessler S, Desai R, Sanderson S, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 May;129(6):959-968. doi: 10.1111/1471-0528.16994. Epub 2021 Nov 25.
    • Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
    • Giri VN, Hartman R, Pritzlaff M, Horton C, Keith SW.
    • JCO Precis Oncol. 2022 May;6(1):e2200234. doi: 10.1200/PO.22.00234.
    • Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.
    • Elhanan G, Kiser D, Neveux I, Dabe S, Bolze A, Metcalf WJ, Lu JT, Grzymski JJ.
    • Front Genet. 2022 Apr 27;13:866169. doi: 10.3389/fgene.2022.866169.
    • Not All Genetic Tests are Created Equal.
    • Cline M, Holdren J.
    • BRCA Exchange. 2022 Apr 14.
    • Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells.
    • Loke J, Alim I, Yam S, Klugman S, Xia LC, Gruber D, Tegay D, LaBella A, Onel K, Ostrer H.
    • HGG Adv. 2022 Jan 8 [eCollection 2022 Apr 14];3(2):100085. doi: 10.1016/j.xhgg.2022.100085.
    • Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment.
    • Secondino A, Starnone F, Veneruso I, Di Tella MA, Conato S, De Angelis C, De Placido S, D'Argenio V.
    • Genes (Basel). 2022 Apr 13;13(4):682. doi: 10.3390/genes13040682.
    • Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience.
    • Van der Merwe NC, Combrink HM, Ntaita KS, Oosthuizen J.
    • Front Genet. 2022 Apr 8;13:834265. doi: 10.3389/fgene.2022.834265.
    • Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China.
    • Sun L, Cui B, Wei X, Sadique Z, Yang L, Manchanda R, Legood R.
    • Cancers (Basel). 2022 Apr 6;14(7):1839. doi: 10.3390/cancers14071839.
    • “You are BRCA2-Positive”: Studies that Have Helped Me.
    • Dreher ME.
    • FORCE. Blog. 2022 Apr 5.
    • Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland.
    • Jasiewicz A, Rudnicka H, Kluzniak W, Gronwald W, Kluz T, Cybulski C, Jakubowska A, Lubinski J, Gronwald J.
    • Hered Cancer Clin Pract. 2022 Apr 5;20(1):12. doi: 10.1186/s13053-022-00219-z.
    • Development of an Open Database of Genes Included in Hereditary Cancer Genetic Testing Panels Available From Major Sources in the US.
    • Geary J, Majumder M, Guerrini C, Cook-Deegan R.
    • JAMA Oncol. 2022 Apr 1;8(4):1-3. doi: 10.1001/jamaoncol.2021.7639.
    • Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases.
    • Kast K, Häfner J, Schröck E, Jahn A, Werner C, Meisel C, Wimberger P.
    • Breast Care (Basel). 2022 Apr;17(2):153-158. doi: 10.1159/000517021. Epub 2021 Jun 17.
    • Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.
    • Rhiem K, Auber B, Briest S, Dikow N, Ditsch N, Dragicevic N, Grill S, Hahnen E, Horvath J, Jaeger B, Kast K, Kiechle M, Leinert E, Morlot S, Püsken M, Schäfer D, Schott S, Schroeder C, Siebers-Renelt U, Solbach C, Weber-Lassalle N, Witzel I, Zeder-Göß C, Schmutzler RK.
    • Breast Care (Basel). 2022 Apr;17(2):199-207. doi: 10.1159/. Epub 2021 Jul 19.
    • Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.
    • Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, Balmaña J, Boccia S, Dabrock P, Emons G, Gaissmaier W, Gronwald J, Houwaart S, Huster S, Kast K, Katalinic A, Linn SC, Moorthie S, Pharoah P, Rhiem K, Spranger T, Stoppa-Lyonnet D, van Delden JJM, van den Bulcke M, Woopen C.
    • Breast Care (Basel). 2022 Apr;17(2):208-223. doi: 10.1159/000517182. Epub 2021 Aug 12.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2022 Apr;16(4):132-143. doi: 10.5489/cuaj.7621.
    • 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes.
    • Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F, Schlecht H, Wallace AJ, Evans DG.
    • Eur J Hum Genet. 2022 Apr;30(4):413-419. doi: 10.1038/s41431-021-01011-8. Epub 2021 Dec 6.
    • Recurring pathogenic variants in the BRCA2 gene in the Ethiopian Jewish population. Founder mutations?
    • Ludman MD, Philipsborn SL, Hartmajer S, Shwartzman NS, Reinstein E.
    • Fam Cancer. 2022 Apr;21(2):121-123. doi: 10.1007/s10689-021-00255-z. Epub 2022 Feb 15.
    • YouTube as an information source on BRCA mutations: implications for patients and professionals.
    • Laforet PE, Yalamanchili B, Hillyer GC, Basch CH.
    • J Community Genet. 2022 Apr;13(2):257-262. doi: 10.1007/s12687-022-00576-1. Epub 2022 Jan 13.
    • Following NCCN guidelines within one hospital system in the United States: Comparison between cancer centers and genetic counselor utilization.
    • Powell K, Rakestraw J, Gupta S, Shou W, Lee K, Leitner O.
    • J Genet Couns. 2022 Apr;31(2):356-363. doi: 10.1002/jgc4.1495. Epub 2021 Aug 9.
    • Large-scale group genetic counseling: Evaluation of a novel service delivery model in a Canadian hereditary cancer clinic.
    • Lohn Z, Fok A, Richardson M, Derocher H, Mung SW, Nuk J, Yuson J, Jevon M, A Schrader K, Sun S.
    • J Genet Couns. 2022 Apr;31(2):459-469. doi: 10.1002/jgc4.1512. Epub 2021 Oct 1.
    • Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
    • Mooney R, Espinel W, Elrick A, Kehoe K, Kohlmann W, Kaphingst KA.
    • J Genet Couns. 2022 Apr;31(2):470-478. doi: 10.1002/jgc4.1513. Epub 2021 Sep 27.
    • Awareness of genetic counseling and genetic testing for hereditary gynecologic cancers among Korean healthcare providers: A survey.
    • Kim M, Cheol Lim M, Ji Nam E, Huang D, Kim S, Jong Yoo H, Lee YY, Chang YJ; on the behalf of the sub-committee of Hereditary Gynecologic Cancers in the Korean Society of Gynecologic Oncology (KSGO).
    • J Genet Couns. 2022 Apr;31(2):546-553. doi: 10.1002/jgc4.1524. Epub 2021 Oct 21.
    • Assessing the relationship between patient preferences for recontact after BRCA1 or BRCA2 genetic testing and their monitoring coping style in a Norwegian sample.
    • Dahle Ommundsen RM, Strømsvik N, Hamang A.
    • J Genet Couns. 2022 Apr;31(2):554-564. doi: 10.1002/jgc4.1526. Epub 2021 Oct 30.
    • In AMIA Keynote, U of Chicago's Olopade Calls for More Diverse Data to Inform Precision Medicine.
    • Versel N.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Mar 28.
    • Conference report
    • You Don’t Have a BRCA Mutation, But Could You Have Lynch Syndrome?
    • [No author given]
    • My Gene Counsel. Genetic Journal. 2022 Mar 22.

    Original research:

    Errors in delivery of cancer genetics services: implications for practice.

    • Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?
    • Jakuboski SH, McDonald JA, Terry MB.
    • NPJ Breast Cancer. 2022 Mar 22;8(1):36. doi: 10.1038/s41523-022-00391-4.
    • Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    • Annoni AM, Longhini C.
    • PLoS One. 2022 Mar 18;17(3):e0265387. doi: 10.1371/journal.pone.0265387.
    • Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    • McBride CM, Pathak S, Johnson CE, Alberg AJ, Bandera EV, Barnholtz-Sloan JS, Bondy ML, Cote ML, Moorman PG, Peres LC, Peters ES, Schwartz AG, Terry PD, Schildkraut JM.
    • Cancer. 2022 Mar 15;128(6):1252-1259. doi: 10.1002/cncr.34053. Epub 2021 Dec 9.
    • Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions.
    • Hesse-Biber S, Seven M, Jiang J, Schaik SV, Dwyer AA.
    • Cancers (Basel). 2022 Mar 15;14(6):1494. doi: 10.3390/cancers14061494.
    • Myriad Genetics Launches New Comprehensive Suite of Cancer Tests With Research Registry.
    • Ray T.
    • GenomeWeb. Business & Policy. Business News. 2022 Mar 14.
    • News

    Press Release: Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care. (Myriad Genetics)

    • New Myriad Product Combines Multiple Cancer Tests.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Mar 14.

    Press Release: Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care. (Myriad Genetics)

    • Breast cancer risk evaluation for the primary care physician.
    • Klassen CL, Gilman E, Kaur A, Lester SP, Pruthi S.
    • Cleve Clin J Med. 2022 Mar 1;89(3):139-146. doi: 10.3949/ccjm.89a.21023.
    • Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.
    • Shah SM, Demidova EV, Lesh RW, Hall MJ, Daly MB, Meyer JE, Edelman MJ, Arora S.
    • Cancer Treat Rev. 2022 Mar;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub 2022 Jan 5.
    • Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.
    • Lux MP, Lewis K, Rider A, Niyazov A.
    • Future Oncol. 2022 Mar;18(9):1089-1101. doi: 10.2217/fon-2021-1387. Epub 2022 Jan 31.
    • Motivations and concerns of patients considering participation in an implementation study of a hereditary cancer risk assessment program in diverse primary care settings.
    • Duenas DM, Shipman KJ, Porter KM, Shuster E, Guerra C, Reyes A, Kauffman TL, Hunter JE, Goddard KAB, Wilfond BS, Kraft SA.
    • Genet Med. 2022 Mar;24(3):610-621. doi: 10.1016/j.gim.2021.11.017. Epub 2021 Nov 23.
    • The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    • Johnston JJ, Brennan ML, Radenbaugh B, Yoo SJ, Hernandez SM; NHGRI Reverse Phenotyping Core, Lewis KL, Katz AE, Manolio TA, Biesecker LG.
    • Genet Med. 2022 Mar;24(3):736-743. doi: 10.1016/j.gim.2021.11.012. Epub 2021 Nov 18.
    • BRCA mutations: Implications of genetic testing in ovarian cancer.
    • Talwar V, Rauthan A.
    • Indian J Cancer. 2022 Mar;59(Supplement):S56-S67. doi: 10.4103/ijc.IJC_1394_20.
    • Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
    • Bellcross CA.
    • Obstet Gynecol Clin North Am. 2022 Mar;49(1):117-147. doi: 10.1016/j.ogc.2021.11.005.
    • Review
    • Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
    • Chavarri-Guerra Y, Villarreal-Garza C, Ferrigno AS, Mohar A, Aguilar D, Alvarez-Gomez RM, Gallardo-Alvarado L, Del Toro-Valero A, Quintero-Beulo G, Gutierrez-Delgado F, Rodriguez-Olivares JL, Ochoa-Chavez MF, Gutierrez-Seymour G, Castillo D, Herzog J, Weitzel JN.
    • Salud Publica Mex. 2022 Feb 25;64(1):41-48. doi: 10.21149/12704.
    • US Bill Seeks to Expand Access to Genetic Cancer Testing for Medicare Members.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Feb 23.
    • Genetic Testing Challenges in Oncology: Muddled Reporting, Interpretation of PALB2 VUS.
    • Ray T.
    • Precision Oncology News. Cancer Specialties. 2022 Feb 23.
    • The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review.
    • Bokkers K, Vlaming M, Engelhardt EG, Zweemer RP, van Oort IM, Kiemeney LALM, Bleiker EMA, Ausems MGEM.
    • Cancers (Basel). 2022 Feb 19;14(4):1059. doi: 10.3390/cancers14041059.
    • BRCA testing and testing results among women 18-65 years old.
    • Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.
    • Prev Med Rep. 2022 Feb 19;26:101738. doi: 10.1016/j.pmedr.2022.101738.
    • Senate Bill Proposes to Expand Medicare Coverage for Hereditary Cancer Testing.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2022 Feb 17.
    • Residential Locale Is Associated with Disparities in Genetic Testing-Related Outcomes Among BRCA1/2-Positive Women.
    • Dibble KE, Connor AE.
    • J Racial Ethn Health Disparities. 2022 Feb 17. doi: 10.1007/s40615-022-01259-w. Epub ahead of print.
    • Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.
    • Clark R, Herrera-Caceres J, Kenk M, Fleshner N.
    • Cancers (Basel). 2022 Feb 16;14(4):1004. doi: 10.3390/cancers14041004.
    • Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.
    • Muessig KR, Zepp JM, Keast E, Shuster EE, Reyes AA, Arnold B, Ingphakorn C, Gilmore MJ, Kauffman TL, Hunter JE, Knerr S, Feigelson HS, Goddard KAB.
    • Hered Cancer Clin Pract. 2022 Feb 10;20(1):7. doi: 10.1186/s13053-022-00213-5.
    • "It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing.
    • Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM.
    • Hered Cancer Clin Pract. 2022 Feb 5;20(1):6. doi: 10.1186/s13053-022-00212-6.
    • Should all patients undergoing genetic testing for hereditary breast cancer syndromes be offered a multigene panel?
    • Silver EL, Niell-Swiller M.
    • Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):36-40. doi: 10.1097/GCO.0000000000000764.
    • Review
    • BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.
    • Petrova D, Cruz M, Sánchez MJ.
    • Breast. 2022 Feb;61:66-76. doi: 10.1016/j.breast.2021.12.005. Epub 2021 Dec 11.
    • An overview of genetic services delivery for hereditary breast cancer.
    • Reid S, Spalluto LB, Lang K, Weidner A, Pal T.
    • Breast Cancer Res Treat. 2022 Feb;191(3):491-500. doi: 10.1007/s10549-021-06478-z. Epub 2022 Jan 26.
    • Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.
    • Lux MP, Decker T, Runkel ED, Niyazov A, Quek RGW, Marschner N, Harbeck N.
    • Breast Care (Basel). 2022 Feb;17(1):40-46. doi: 10.1159/000513596. Epub 2021 Feb 18.
    • A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.
    • Johnson K, Saylor K, Guynn I, Hicklin K, Berg JS, Lich KH.
    • Genet Med. 2022 Feb;24(2):262-288. doi: 10.1016/j.gim.2021.10.008. Epub 2021 Dec 7.
    • Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants.
    • Douglas MP, Lin GA, Trosman JR, Phillips KA.
    • J Community Genet. 2022 Feb;13(1):75-80. doi: 10.1007/s12687-021-00563-y. Epub 2021 Nov 6.
    • Polygenic risk in familial breast cancer: Changing the dynamics of communicating genetic risk.
    • Gregory G, Das Gupta K, Meiser B, Barlow-Stewart K, Geelan-Small P, Kaur R, Scheepers-Joynt M, McInerny S, Taylor S, Antill Y, Salmon L, Smyth C, Young MA, James PA, Yanes T.
    • J Genet Couns. 2022 Feb;31(1):120-129. doi: 10.1002/jgc4.1458. Epub 2021 Jul 5.
    • Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers.
    • Vasigh M, Eslami B, Elahi A, Kaviani A, Shirkoohi R, Majidzadeh K, Nazarian N, Omranipour R.
    • Mol Genet Genomic Med. 2022 Feb;10(2):e1867. doi: 10.1002/mgg3.1867. Epub 2022 Jan 12.
    • BRCA1/2 Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome.
    • Le TN, Tran VK, Nguyen TT, Vo NS, Hoang TH, Vo HL, Nguyen TT, Nguyen PD, Nguyen VT, Ta TV, Tran HT.
    • Genes (Basel). 2022 Jan 29;13(2):268. doi: 10.3390/genes13020268.
    • Tennis Star Chris Evert Teaches Us That Genetic Testing Is A Lifetime Match.
    • Matloff E.
    • Forbes. Healthcare. 2022 Jan 17.

    News: Tennis Star Chris Evert Teaches Us That Genetic Testing Is a Lifetime Match. (My Gene Counsel)

    • Remote AI Supported E-Multidisciplinary Oncology Conference in Breast Cancer as a Technology and Method to Optimize Outcomes in the Peripheries.
    • Mammas CS, Mamma AS, Papaxoinis G, Georgiou I.
    • Stud Health Technol Inform. 2022 Jan 14;289:309-312. doi: 10.3233/SHTI210921.
    • Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative.
    • Greve V, Odom K, Pudner S, Lamb NE, Cooper SJ, East K.
    • HGG Adv. 2021 Aug 24 [eCollection 2022 Jan 13];3(1):100055. doi: 10.1016/j.xhgg.2021.100055.
    • Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer”.
    • Manchanda R.
    • Cancers (Basel). 2022 Jan 10;14(2):319. doi: 10.3390/cancers14020319.
    • Pathogenic Variant Profile of Hereditary Cancer Syndromes in a Vietnamese Cohort.
    • Tran VT, Nguyen ST, Pham XD, Phan TH, Nguyen VC, Nguyen HT, Nguyen HP, Doan PTT, Le TA, Nguyen BT, Jasmine TX, Nguyen DS, Nguyen HL, Nguyen NM, Do DX, Tran VU, Nguyen HHT, Le MP, Nguyen YN, Do TTT, Truong DK, Tang HS, Phan MD, Nguyen HN, Giang H, Tu LN.
    • Front Oncol. 2022 Jan 5;11:789659. doi: 10.3389/fonc.2021.789659.
    • Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Jan 5.

    Original research:

    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.

    • Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    • Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC.
    • Cancer. 2022 Jan 1;128(1):94-102. doi: 10.1002/cncr.33866. Epub 2021 Aug 23.

    Editorial:

    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?

    • Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
    • Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Tsoulos N, Boukovinas I, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Kapsimalis A, Xepapadakis G, Psyrri A, Banu E, Eniu DT, Blidaru A, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G.
    • Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):60-78. doi: 10.21873/cgp.20304.
    • Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
    • Vegunta S, Bhatt AA, Choudhery SA, Pruthi S, Kaur AS.
    • Breast Cancer. 2022 Jan;29(1):19-29. doi: 10.1007/s12282-021-01298-x. Epub 2021 Oct 19.
    • Review
    • Genetic testing in Non-Hispanic Black women with breast cancer treated within an equal-access healthcare system.
    • Vargason AB, Turner CE, Shriver CD, Ellsworth RE.
    • Genet Med. 2022 Jan;24(1):232-237. doi: 10.1016/j.gim.2021.08.002. Epub 2021 Nov 30.

    Podcast: January 2022: Providing access to quality healthcare for Non-Hispanic Black women reduces mortality. (Genetics in Medicine. GenePod)

    • Screening of CNVs using NGS data improves mutation detection yield and decreases costs in genetic testing for hereditary cancer.
    • Moreno-Cabrera JM, Del Valle J, Feliubadaló L, Pineda M, González S, Campos O, Cuesta R, Brunet J, Serra E, Capellà G, Gel B, Lázaro C.
    • J Med Genet. 2022 Jan;59(1):75-78. doi: 10.1136/jmedgenet-2020-107366. Epub 2020 Nov 20.
    • Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies.
    • Dillon J, Ademuyiwa FO, Barrett M, Moss HA, Wignall E, Menendez C, Hughes KS, Plichta JK.
    • Surg Oncol Clin N Am. 2022 Jan;31(1):109-126. doi: 10.1016/j.soc.2021.08.004. Epub 2021 Oct 19.
    • Review
    • Genetic testing for hereditary predisposition to breast cancer in the real world: Initial experience.
    • da Silva Fontinele DR, Assunção Ribeiro da Costa RE, da Silva Magalhães MK, Vieira SC.
    • Breast Dis. 2022;41(1):249-254. doi: 10.3233/BD-210082.
    • Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    • Ademuyiwa FO, Salyer P, Tao Y, Luo J, Hensing WL, Afolalu A, Peterson LL, Weilbaecher K, Housten AJ, Baumann AA, Desai M, Jones S, Linnenbringer E, Plichta J, Bierut L.
    • J Clin Oncol. 2021 Dec 20;39(36):4020-4028. doi: 10.1200/JCO.21.01426. Epub 2021 Oct 18.

    Commentary:

    Acknowledging Disparities in Hereditary Cancer Testing.

    Press: Physician Bias May Contribute to Lower Genetic Testing Rates Among Black Women, Study Suggests. (Precision Oncology News)

    Press: Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows. (Inside Precision Medicine)

    • Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.
    • Shen L, Zhang S, Wang K, Wang X.
    • Front Oncol. 2021 Dec 1;11:740227. doi: 10.3389/fonc.2021.740227.

    Commentary:

    Editorial: Familial Cancer in China: From Detection to Screening and Management.

    • Hereditary Cancer Risk Using a Genetic Chatbot Before Routine Care Visits.
    • Nazareth S, Hayward L, Simmons E, Snir M, Hatchell KE, Rojahn S, Slotnick RN, Nussbaum RL.
    • Obstet Gynecol. 2021 Dec 1;138(6):860-870. doi: 10.1097/AOG.0000000000004596.
    • Underutilisation of breast cancer prevention medication in Australia.
    • Macdonald C, Chamberlain JA, Mazza D, Milne RL; kConFab investigators, Phillips KA.
    • Breast. 2021 Dec;60:35-37. doi: 10.1016/j.breast.2021.08.013. Epub 2021 Aug 23.
    • Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.
    • Brédart A, De Pauw A, Anota A, Tüchler A, Dick J, Müller A, Kop JL, Rhiem K, Schmutzler R, Devilee P, Stoppa-Lyonnet D, Dolbeault S.
    • Breast. 2021 Dec;60:38-44. doi: 10.1016/j.breast.2021.08.011. Epub 2021 Aug 23.
    • Somatic mosaics in hereditary tumor predisposition syndromes.
    • Steinke-Lange V, de Putter R, Holinski-Feder E, Claes KB.
    • Eur J Med Genet. 2021 Dec;64(12):104360. doi: 10.1016/j.ejmg.2021.104360. Epub 2021 Oct 13.
    • Positive predictive value highlights four novel candidates for actionable genetic screening from analysis of 220,000 clinicogenomic records.
    • Schiabor Barrett KM, Bolze A, Ni Y, White S, Isaksson M, Sharma L, Levin E, Lee W, Grzymski JJ, Lu JT, Washington NL, Cirulli ET.
    • Genet Med. 2021 Dec;23(12):2300-2308. doi: 10.1038/s41436-021-01293-9. Epub 2021 Aug 13.
    • The role of psychosocial factors in Black women's self-efficacy in receiving genetic counseling and testing.
    • Ding H, Sutton AL, Hurtado-de-Mendoza A, Sheppard VB.
    • J Genet Couns. 2021 Dec;30(6):1719-1726. doi: 10.1002/jgc4.1439. Epub 2021 Jun 4.
    • Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility.
    • Tudini E, Davidson AL, Dressel U, Andrews L, Antill Y, Crook A, Field M, Gattas M, Harris R, Kirk J, Pachter N, Salmon L, Susman R, Townshend S, Trainer AH, Tucker KM, Mitchell G, James PA, Ward RL, Mar Fan H, Poplawski NK, Spurdle AB.
    • J Med Genet. 2021 Dec;58(12):853-858. doi: 10.1136/jmedgenet-2020-107140. Epub 2020 Nov 9.
    • Genetic Testing Challenges in Oncology: No Follow-up on Insurer Denial Delays Cancer Risk Management.
    • Ray T.
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 Nov 29.
    • Genetic Risks for Cancer Should Not Mean Financial Hardship.
    • Pierson L, Pierson E.
    • New York Times. Opinion. 2021 Nov 26.
    • Commentary

    Commentary: The Medical Side Effect We Must Stop Ignoring: Financial Toxicity. (Forbes)

    • Survey Reveals Groups, Strategies to Focus Awareness Efforts for Cancer Germline Testing.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 23.
    • News
    • UK Women's Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study.
    • Kelley-Jones C, Scott S, Waller J.
    • Cancers (Basel). 2021 Nov 19;13(22):5813. doi: 10.3390/cancers13225813.
    • Conference Session Highlight: I'm Not White, Can I Still Have a Mutation?
    • Stallings E, Goldberg D.
    • FORCE. Blog. 2021 Nov 19.
    • Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
    • Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, Goebell PJ, Stöhr R, Hartmann A, Wullich B, Taubert H, Wach S.
    • Cells. 2021 Nov 18;10(11):3223. doi: 10.3390/cells10113223.
    • Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    • Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS.
    • Cancer Res Treat. 2021 Nov 17. doi: 10.4143/crt.2021.978. Epub ahead of print.
    • Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
    • Jalloul N, Gomy I, Stokes S, Gusev A, Johnson BE, Lindeman NI, Macconaill L, Ganesan S, Garber JE, Khiabanian H.
    • JCO Precis Oncol. 2021 Nov 17;5:PO.21.00279. doi: 10.1200/PO.21.00279.

    Letter, Commentary:

    Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing-A Quality Assurance Strategy.

    Letter, Reply:

    Reply to T. Ménard.

    • Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time?
    • De Silva DL, James PA, Mann GB, Lindeman GJ.
    • Med J Aust. 2021 Nov 15;215(10):449-453. doi: 10.5694/mja2.51317. Epub 2021 Oct 22.
    • Commentary
    • Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
    • Kauffman TL, Prado YK, Reyes AA, Zepp JM, Sawyer J, White LL, Martucci J, Salas SB, Vertrees S, Rope AF, Weinmann S, Henrikson NB, Lee SS, Feigelson HS, Hunter JE.
    • J Pers Med. 2021 Nov 13;11(11):1194. doi: 10.3390/jpm11111194.
    • Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs.
    • Perkins AT, Haslem D, Goldsberry J, Shortt K, Sittig L, Raghunath S, Giauque C, Snow S, Fulde G, Moulton B, Jones D, Nadauld L.
    • Cancers (Basel). 2021 Nov 10;13(22):5612. doi: 10.3390/cancers13225612.
    • A Review of Breast Cancer Risk Factors in Adolescents and Young Adults.
    • McVeigh UM, Tepper JW, McVeigh TP.
    • Cancers (Basel). 2021 Nov 5;13(21):5552. doi: 10.3390/cancers13215552.
    • Challenges and Errors in Genetic Testing: The Fifth Case Series.
    • Farmer MB, Bonadies DC, Pederson HJ, Mraz KA, Whatley JW, Darnes DR, Denton JJ, De Rosa D, Heatherly A, Kenney J, Lane K, Paul D, Pelletier RC, Shannon K, Williams D, Matloff ET.
    • Cancer J. 2021 Nov-Dec 01;27(6):417-422. doi: 10.1097/PPO.0000000000000553.
    • Case series
    • Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1/2 mutations.
    • Smith MJ, Gerber D, Olsen A, Khouri OR, Wang Y, Liu M, Smith J, Pothuri B.
    • Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23.
    • Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.
    • Combrink HM, Oosthuizen J, Visser B, Chabilal N, Buccimazza I, Foulkes WD, van der Merwe NC.
    • Cancer Genet. 2021 Nov;258-259:1-6. doi: 10.1016/j.cancergen.2021.06.002. Epub 2021 Jun 15.

    Dataset description:

    A South African Indian population group dataset for breast cancer and BRCA1/2 variants.

    • BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
    • Montalban G, Bonache S, Bach V, Gisbert-Beamud A, Tenés A, Moles-Fernández A, López-Fernández A, Carrasco E, Balmaña J, Diez O, Gutiérrez-Enríquez S.
    • Cancer Genet. 2021 Nov;258-259:10-17. doi: 10.1016/j.cancergen.2021.06.003. Epub 2021 Jun 18.
    • When cascade testing for familial variant seems inadequate to provide clinically actionable information for blood relatives.
    • Apostolou P, Fostira F, Fountzilas G, Razis E, Yannoukakos D, Konstantopoulou I.
    • Cancer Genet. 2021 Nov;258-259:49-50. doi: 10.1016/j.cancergen.2021.08.003. Epub 2021 Aug 24.
    • Case report
    • Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).
    • McReynolds LJ, Biswas K, Giri N, Sharan SK, Alter BP.
    • Cancer Genet. 2021 Nov;258-259:101-109. doi: 10.1016/j.cancergen.2021.10.001. Epub 2021 Oct 4.
    • HerediCaRe: Dokumentations- und IT-Lösung eines spezialisierten Registers für erblichen Brust- und Eierstockkrebs [HerediCaRe: Documentation and IT Solution of a Specialized Registry for Hereditary Breast and Ovarian Cancer].
    • Engel C, Wieland K, Zachariae S, Bucksch K, Enders U, Schoenwiese U, Yahiaoui-Doktor M, Keupp K, Waha A, Hahnen E, Remy R, Ernst C, Loeffler M, Schmutzler RK.
    • Gesundheitswesen. 2021 Nov;83(S 01):S12-S17. German. doi: 10.1055/a-1658-0313. Epub 2021 Nov 3.
    • Massive parallel sequencing in individuals with multiple primary tumours reveals the benefit of re-analysis.
    • Karin W, Håkan T, Daniel N, Emma T.
    • Hered Cancer Clin Pract. 2021 Oct 28;19(1):46. doi: 10.1186/s13053-021-00203-z.
    • MSK Fellows Develop Online Resource to Increase Awareness of Genetic Cascade Testing.
    • Kanski A.
    • Precision Oncology News. Technology. 2021 Oct 21.
    • News
    • Germline Testing in Prostate Cancer: When and Who to Test.
    • Sokolova A, Cheng H.
    • Oncology (Williston Park). 2021 Oct 20;35(10):645-653. doi: 10.46883/ONC.2021.3510.0645.
    • Outcomes4Me Incorporates NCCN Hereditary Cancer Risk Testing Guidelines Into Patient-Facing App.
    • [No author given]
    • Precision Oncology News. Disease Areas. 2021 Oct 18.
    • IMProving care After inherited Cancer Testing (IMPACT) study: protocol of a randomized trial evaluating the efficacy of two interventions designed to improve cancer risk management and family communication of genetic test results.
    • Cragun D, Beckstead J, Farmer M, Hooker G, Dean M, Matloff E, Reid S, Tezak A, Weidner A, Whisenant JG, Pal T.
    • BMC Cancer. 2021 Oct 13;21(1):1099. doi: 10.1186/s12885-021-08822-4.
    • Invitae, Outcomes4Me Collaborate to Improve Breast Cancer Genetic Testing Access.
    • [No author given]
    • GenomeWeb. Diagnostics. 2021 Oct 8.
    • Fragmented responsibility: views of Israeli HCPs regarding patient recontact following variant reclassification.
    • Fridman AL, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Community Genet. 2021 Oct 5:1–6. doi: 10.1007/s12687-021-00556-x. Epub ahead of print.
    • A culturally targeted video to promote genetic counseling in a community sample of at-risk US Latina women: The role of the concrete mindset.
    • Carrera P, Sheppard VB, Caballero A, Gómez-Trillos S, Hurtado-de-Mendoza A.
    • J Community Psychol. 2021 Oct 4. doi: 10.1002/jcop.22718. Epub ahead of print.
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
    • Bernstein-Molho R, Galmor L, Laitman Y, Segev S, Friedman E.
    • Cancer. 2021 Oct 1;127(19):3599-3604. doi: 10.1002/cncr.33560. Epub 2021 Jun 22.
    • Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    • Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK.
    • Cancer. 2021 Oct 1;127(19):3605-3613. doi: 10.1002/cncr.33668. Epub 2021 Jun 22.
    • Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    • Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, Shao Z, Yang W, Zhou X.
    • J Cancer Res Clin Oncol. 2021 Oct;147(10):2935-2944. doi: 10.1007/s00432-021-03696-2. Epub 2021 Jul 13.
    • Genetic counseling clinical documentation: Practice Resource of the National Society of Genetic Counselors.
    • Hunt Brendish K, Patel D, Yu K, Alexander CK, Lemons J, Gunter A, Carmany EP.
    • J Genet Couns. 2021 Oct;30(5):1336-1353. doi: 10.1002/jgc4.1491. Epub 2021 Aug 14.
    • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    • Simões Corrêa Galendi J, Vennedey V, Kentenich H, Stock S, Müller D.
    • Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
    • Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics.
    • Mampunye L, van der Merwe NC, Grant KA, Peeters AV, Torrorey-Sawe R, French DJ, Moremi KE, Kidd M, van Eeden PC, Pienaar FM, Kotze MJ.
    • Front Oncol. 2021 Sep 29;11:619817. doi: 10.3389/fonc.2021.619817.
    • Genetic Testing Challenges in Oncology: BRCA1 Variant Downgraded After Risk-Reducing Surgery.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Sep 29.
    • Coping response and family communication of cancer risk in men harboring a BRCA mutation: A mixed methods study.
    • Dwyer AA, Hesse-Biber S, Shea H, Zeng Z, Yi S.
    • Psychooncology. 2021 Sep 28. doi: 10.1002/pon.5831. Epub ahead of print.
    • Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.
    • Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G.
    • J Med Genet. 2021 Sep 23:jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print.
    • Case report: Antenatal diagnostic of a polymalformative syndrome due to biallelic BRCA2 mutations.
    • Anquetil A, Khung Savatovsky S, Gavard L, Bazin A, Guimiot F, Dubourg C, Mandelbrot L, Picone O.
    • Clin Case Rep. 2021 Sep 22;9(9):e04838. doi: 10.1002/ccr3.4838.
    • Building the What Comes Next Cohort for BRCA1 and BRCA2 testing: a descriptive analysis.
    • Dossa F, Metcalfe K, Sutradhar R, Little T, Eisen A, Chun K, Meschino WS, Velsher L, Ellis JL, Baxter NN.
    • CMAJ Open. 2021 Sep 21;9(3):E874-E885. doi: 10.9778/cmajo.20200228.
    • Researchers Call for More Uniformity in Cancer Genetic Testing, Risk Guidelines in Europe.
    • Kanski A.
    • Precision Oncology News. 2021 Sep 19.
    • News
    • Identification of a novel pathogenic variant in PALB2 and BARD1 genes by a multigene sequencing panel in triple negative breast cancer in Morocco.
    • Laraqui A, Cavaillé M, Uhrhammer N, ElBiad O, Bidet Y, El Rhaffouli H, El Anaz H, Rahali DM, Kouach J, Guelzim K, Badaoui B, AlBouzidi A, Oukabli M, Tanz R, Sbitti Y, Ichou M, Ennibi K, Sekhsokh Y, Bignon YJ.
    • J Genomics. 2021 Sep 18;9:43-54. doi: 10.7150/jgen.61713.
    • Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
    • Augustinsson A, Nilsson MP, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Breast Cancer Res Treat. 2021 Sep 16:1–9. doi: 10.1007/s10549-021-06351-z. Epub ahead of print.
    • Feasibility of genetic testing for cancer risk assessment programme in Nigeria.
    • Adejumo PO, Aniagwu TIG, Awolude OA, Oni AO, Ajayi OO, Fagbenle O, Ogungbade D, Kochheiser M, Ogundiran T, Olopade OI.
    • Ecancermedicalscience. 2021 Sep 7;15:1283. doi: 10.3332/ecancer.2021.1283.
    • Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
    • Tung N, Desai N.
    • J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761. Epub ahead of print.

    Original research:

    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

    Original research:

    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

    • Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    • Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart TL, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Cancer. 2021 Sep 1;127(17):3082-3091. doi: 10.1002/cncr.33625. Epub 2021 May 13.
    • Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
    • Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D Jr, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN.
    • JCO Precis Oncol. 2021 Sep 1;5:PO.21.00238. doi: 10.1200/PO.21.00238.

    Research news: Men Give Thumbs Up to Video on Genetic Testing in Prostate Cancer. (Medscape Oncology)

    • Current Testing Guidelines: A Retrospective Analysis of a Community-Based Hereditary Cancer Program.
    • Ward M, Elder B, Habtemariam M.
    • J Adv Pract Oncol. 2021 Sep;12(7):693-701. doi: 10.6004/jadpro.2021.12.7.3. Epub 2021 Sep 1.
    • Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    • Wei J, Yang W, Shi Z, Lu L, Wang Q, Resurreccion WK, Engelmann V, Zheng SL, Hulick PJ, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J.
    • Prostate. 2021 Sep;81(13):1002-1008. doi: 10.1002/pros.24195. Epub 2021 Jul 12.
    • Genetic predisposition to male breast cancer in Poland.
    • Szwiec M, Tomiczek-Szwiec J, Kluzniak W, Wokolorczyk D, Osowiecka K, Sibilski R, Wachowiak M, Gronwald J, Gronwald H, Lubinski J, Cybulski C, Narod SA, Huzarski T.
    • BMC Cancer. 2021 Aug 30;21(1):975. doi: 10.1186/s12885-021-08718-3.
    • Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations.
    • Meshkani Z, Aboutorabi A, Moradi N, Langarizadeh M, Motlagh AG.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):35. doi: 10.1186/s13053-021-00191-0.
    • Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.
    • Hendricks-Sturrup RM, Joseph L, Lu CY.
    • J Pers Med. 2021 Aug 27;11(9):850. doi: 10.3390/jpm11090850.
    • Preventive population genomics: The model of BRCA related cancers.
    • Reisel D, Baran C, Manchanda R.
    • Adv Genet. 2021;108:1-33. doi: 10.1016/bs.adgen.2021.08.001. Epub 2021 Aug 26.
    • Review. Book chapter
    • Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    • Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O'Reilly EM, Seufferlein T.
    • Cancers (Basel). 2021 Aug 24;13(17):4259. doi: 10.3390/cancers13174259.
    • "Being proactive, not reactive": exploring perceptions of genetic testing among White, Latinx, and Pacific Islander Populations.
    • Chavez-Yenter D, Vagher J, Clayton MF, Rindler M, Shukovich M, Kaphingst KA.
    • J Community Genet. 2021 Aug 20. doi: 10.1007/s12687-021-00542-3. Epub ahead of print.
    • Genetic counselling as a route to enhanced autonomy: using a sequential mixed methods research approach to develop a theory regarding presymptomatic genetic testing for young adults at risk of inherited cancer syndromes.
    • Godino L, Turchetti D, Jackson L, Hennessy C, Skirton H.
    • J Community Genet. 2021 Aug 20. doi: 10.1007/s12687-021-00548-x. Epub ahead of print.
    • Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America.
    • Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, Clague-Dehart J, Alvarez-Gómez RM, Wegman-Ostrosky T, Mohar A, Mora P, Del Toro-Valero A, Daneri-Navarro A, Rodriguez Y, Cruz-Correa M, Ashton-Prolla P, Alemar B, Mejia R, Gallardo L, Shaw R, Yang K, Cervantes A, Tsang K, Nehoray B, Barrera Saldana H, Neuhausen S, Weitzel JN.
    • NPJ Breast Cancer. 2021 Aug 19;7(1):107. doi: 10.1038/s41523-021-00317-6.
    • Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours.
    • Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP.
    • Cancers (Basel). 2021 Aug 18;13(16):4150. doi: 10.3390/cancers13164150.
    • Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability.
    • Evans DG, van Veen EM, Woodward ER, Harkness EF, Ellingford JM, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.
    • Cancers (Basel). 2021 Aug 18;13(16):4154. doi: 10.3390/cancers13164154.
    • Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
    • Murali K, Dwarte TM, Nikfarjam M, Tucker KM, Vaughan RB, Efthymiou M, Collins A, Spigelman AD, Salmon L, Johns AL, Williams DB, Delatycki MB, John T, Stoita A.
    • Hered Cancer Clin Pract. 2021 Aug 16;19(1):33. doi: 10.1186/s13053-021-00190-1.
    • Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 13.

    Original research:

    Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.

    • Genetic Testing Challenges in Oncology: Consumer Genomics Reveals More Than Fun Traits.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Aug 3.
    • Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.
    • Ficarazzi F, Vecchi M, Ferrari M, Pierotti MA.
    • Breast. 2021 Aug;58:121-129. doi: 10.1016/j.breast.2021.04.011. Epub 2021 May 12.
    • Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
    • Bono M, Fanale D, Incorvaia L, Cancelliere D, Fiorino A, Calò V, Dimino A, Filorizzo C, Corsini LR, Brando C, Madonia G, Cucinella A, Scalia R, Barraco N, Guadagni F, Pedone E, Badalamenti G, Russo A, Bazan V.
    • ESMO Open. 2021 Aug;6(4):100235. doi: 10.1016/j.esmoop.2021.100235. Epub 2021 Aug 7.
    • Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
    • Boilève A, Lavaud P, Caron O.
    • Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
    • Letter, Comment

    Review:

    Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

    • Genetic counselor experiences with telehealth before and after COVID-19.
    • Mills R, MacFarlane IM, Caleshu C, Ringler MA, Zierhut HA.
    • J Genet Couns. 2021 Aug;30(4):999-1009. doi: 10.1002/jgc4.1465. Epub 2021 Jul 7.
    • 'Steep learning curves' to 'Smooth Sailing': A reappraisal of telegenetics amidst the COVID-19 pandemic.
    • Mueller R, Schindewolf E, Williams S, Jay Kessler L.
    • J Genet Couns. 2021 Aug;30(4):1010-1023. doi: 10.1002/jgc4.1487. Epub 2021 Aug 6.
    • Sudden shift to remote genetic counseling during the COVID-19 pandemic: Experiences of genetics professionals in Italy.
    • Turchetti D, Battistuzzi L, Bertonazzi B, Godino L.
    • J Genet Couns. 2021 Aug;30(4):1024-1037. doi: 10.1002/jgc4.1441. Epub 2021 Jun 6.
    • Pursuing germline genome sequencing to reduce illness uncertainty may involve additional uncertainties for cancer patients: A mixed-methods study.
    • Bartley N, Best M, Butow P.
    • J Genet Couns. 2021 Aug;30(4):1143-1155. doi: 10.1002/jgc4.1398. Epub 2021 Mar 31.
    • Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    • Siebert AL, Szymaniak BM, Numan Y, Morgans AK.
    • Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.
    • Review
    • Germline Predisposition to Prostate Cancer in Diverse Populations.
    • Bree KK, Henley PJ, Pettaway CA.
    • Urol Clin North Am. 2021 Aug;48(3):411-423. doi: 10.1016/j.ucl.2021.03.008. Epub 2021 Jun 12.
    • Review
    • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    • Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.
    • Breast Cancer Res Treat. 2021 Jul 26. doi: 10.1007/s10549-021-06333-1. Epub ahead of print.
    • Volpara Adding Invitae Genetic Test Ordering to Breast Risk Software Platform.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Jul 22.
    • Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.
    • Abdel-Razeq H, Abujamous L, Abunasser M, Edaily S, Bater R.
    • Sci Rep. 2021 Jul 21;11(1):14906. doi: 10.1038/s41598-021-94403-1.
    • Incidental findings from cancer next generation sequencing panels.
    • Maani N, Panabaker K, McCuaig JM, Buckley K, Semotiuk K, Farncombe KM, Ainsworth P, Panchal S, Sadikovic B, Armel SR, Lin H, Kim RH.
    • NPJ Genom Med. 2021 Jul 19;6(1):63. doi: 10.1038/s41525-021-00224-6.
    • Search Behavior Regarding Cancer Susceptibility Genes Using a Clinical Decision Support Tool for Gene-Specific Penetrance: Content Analysis.
    • Yin K, Zhou J, Singh P, Wang J, Braun D, Hughes KS.
    • JMIR Cancer. 2021 Jul 13;7(3):e28527. doi: 10.2196/28527.
    • Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.
    • de Belvis AG, Pellegrino R, Castagna C, Morsella A, Pastorino R, Boccia S.
    • J Pers Med. 2021 Jul 13;11(7):654. doi: 10.3390/jpm11070654.
    • Development and pilot testing of a training for bilingual community education professionals about hereditary breast and ovarian cancer among Latinas: ÁRBOLES Familiares.
    • Vadaparampil ST, Moreno Botero L, Fuzzell L, Garcia J, Jandorf L, Hurtado-de-Mendoza A, Campos-Galvan C, Peshkin BN, Schwartz MD, Lopez K, Ricker C, Fiallos K, Quinn GP, Graves KD.
    • Transl Behav Med. 2021 Jul 13:ibab093. doi: 10.1093/tbm/ibab093. Epub ahead of print.
    • Hereditary breast cancer and ancestry in the Madeira archipelago: an exploratory study.
    • Miguel I, Rodrigues F, Fragoso S, Freixo J, Clara A, Luís A, Bento S, Fernandes M, Bacelar F, Câmara S, Parreira J, Duarte T, Rodrigues P, Santos S, Vaz F.
    • Ecancermedicalscience. 2021 Jul 5;15:1261. doi: 10.3332/ecancer.2021.1261.
    • Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.
    • Smit AK, Sharman AR, Espinoza D, Wallingford C, Young MA, Dunlop K, Tiller J, Newson AJ, Meiser B, Cust AE, Yanes T.
    • Clin Genet. 2021 Jul 3. doi: 10.1111/cge.14025. Epub ahead of print.
    • Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.
    • Domchek SM, Yao S, Chen F, Hu C, Hart SN, Goldgar DE, Nathanson KL, Ambrosone CB, Haiman CA, Couch FJ, Polley EC, Palmer JR; CARRIERS Consortium.
    • JAMA Oncol. 2021 Jul 1;7(7):1045-1050. doi: 10.1001/jamaoncol.2021.1492.

    Research news: Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women. (FORCE. XRAY)

    Research news: UPenn Study Finds Similar Rates of Risk Mutations Among Black, White Breast Cancer Patients. (Precision Oncology News)

    • Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.
    • Sorscher S.
    • JAMA Oncol. 2021 Jul 1;7(7):1070. doi: 10.1001/jamaoncol.2021.1002.
    • Letter, Comment

    Letter, Reply:

    Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer—Reply

    Original research:

    Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.

    • Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.
    • Colas C, De Pauw A, Golmard L.
    • JAMA Oncol. 2021 Jul 1;7(7):1071. doi: 10.1001/jamaoncol.2021.1005.
    • Letter, Comment

    Letter, Reply:

    Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer-Reply.

    Original research:

    Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.

    • Implementing Primary Care Mediated Population Genetic Screening Within an Integrated Health System.
    • David SP, Dunnenberger HM, Ali R, Matsil A, Lemke AA, Singh L, Zimmer A, Hulick PJ.
    • J Am Board Fam Med. 2021 Jul-Aug;34(4):861-865. doi: 10.3122/jabfm.2021.04.200381.
    • Precision medicine in breast cancer: From clinical trials to clinical practice.
    • Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G.
    • Cancer Treat Rev. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12.
    • Review
    • DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations.
    • Yang M, Fan Y, Wu ZY, Gu J, Feng Z, Zhang Q, Han S, Zhang Z, Li X, Hsueh YC, Ni Y, Li X, Li J, Hu M, Li W, Gao H, Yang C, Zhang C, Zhang L, Zhu T, Cheng M, Ji F, Xu J, Cui H, Tan G, Zhang MQ, Liang C, Liu Z, Song YQ, Niu G, Wang K.
    • EBioMedicine. 2021 Jul;69:103446. doi: 10.1016/j.ebiom.2021.103446. Epub 2021 Jun 19.
    • The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    • Escudeiro C, Pinto C, Vieira J, Peixoto A, Pinto P, Pinheiro M, Santos C, Guerra J, Lisboa S, Santos R, Silva J, Leal C, Coimbra N, Lopes P, Ferreira M, Sousa AB, Teixeira MR.
    • Fam Cancer. 2021 Jul;20(3):173-180. doi: 10.1007/s10689-020-00212-2. Epub 2020 Oct 14.
    • A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis.
    • Katki HA, Bebu I.
    • J R Stat Soc Ser A Stat Soc. 2021 Jul;184(3):887-903. doi: 10.1111/rssa.12680. Epub 2021 Mar 23.
    • Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
    • Kim SH, Kang CM.
    • Ann Hepatobiliary Pancreat Surg. 2021 Jun 30;25(Suppl 1):S149. doi: 10.14701/ahbps.BP-PP-1-2.
    • Genetic Testing Challenges in Oncology: Inaccurate Patient Claims Complicate Cancer Risk Management.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Jun 30.

    Blog post: Genetic Testing Challenges in Oncology: Inaccurate Patient Claims Complicate Cancer Risk Management. (My Gene Counsel)

    • Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper.
    • Cousens NE, Tiller J, Meiser B, Barlow-Stewart K, Rowley S, Ko YA, Mahale S, Campbell IG, Kaur R, Bankier A, Burnett L, Jacobs C, James PA, Trainer A, Neil S, Delatycki MB, Andrews L.
    • BMJ Open. 2021 Jun 25;11(6):e041186. doi: 10.1136/bmjopen-2020-041186.
    • Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
    • Bekos C, Grimm C, Kranawetter M, Polterauer S, Oberndorfer F, Tan Y, Müllauer L, Singer CF.
    • J Pers Med. 2021 Jun 24;11(7):593. doi: 10.3390/jpm11070593.
    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial.
    • Dwyer AA, Shen H, Zeng Z, Gregas M, Zhao M.
    • Genes (Basel). 2021 Jun 20;12(6):941. doi: 10.3390/genes12060941.
    • A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.
    • Sahin I, Saat H.
    • Mol Biol Rep. 2021 Jun 19. doi: 10.1007/s11033-021-06499-3. Epub ahead of print.
    • A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults.
    • Jordan F, Huber S, Sommer S, Schenkirsch G, Frühwald MC, Trepel M, Claus R, Kuhlen M.
    • Cancers (Basel). 2021 Jun 17;13(12):3033. doi: 10.3390/cancers13123033.
    • Ashkenazi Dads Can Pass the BRCA Mutation to Their Kids. It Turns Out I Did.
    • Hertz B.
    • Kveller. 2021 Jun 14.

    Blog post: Surviving, and Thriving, as a Dad with a Cancer Gene Mutation. (FORCE Blog)

    • Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.
    • Wang A, Everett JN, Chun J, Cen C, Simeone DM, Schnabel F.
    • Sci Rep. 2021 Jun 14;11(1):12491. doi: 10.1038/s41598-021-91971-0.
    • Recent Insights on Genetic Testing in Primary Prostate Cancer.
    • Kafka M, Surcel C, Heidegger I.
    • Mol Diagn Ther. 2021 Jun 12. doi: 10.1007/s40291-021-00529-3. Epub ahead of print.
    • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).
    • Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J.
    • J Pers Med. 2021 Jun 4;11(6):511. doi: 10.3390/jpm11060511.
    • Out-of-pocket and private pay in clinical genetic testing: a scoping review.
    • Grant P, Langlois S, Lynd LD; GenCOUNSEL Study, Austin JC, Elliott AM.
    • Clin Genet. 2021 Jun 3. doi: 10.1111/cge.14006. Epub ahead of print.
    • Review
    • Quality and Quantity: How to Organize a Countrywide Genetic Counseling and Testing.
    • Schmutzler RK.
    • Breast Care (Basel). 2021 Jun;16(3):196-201. doi: 10.1159/000515429. Epub 2021 May 7.
    • From BRCA1 to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes.
    • Woodward ER, van Veen EM, Evans DG.
    • Breast Care (Basel). 2021 Jun;16(3):202-213. doi: 10.1159/000515319. Epub 2021 Mar 31.
    • Cancer genetic testing in marginalized groups during an era of evolving healthcare reform.
    • Modell SM, Allen CG, Ponte A, Marcus G.
    • J Cancer Policy. 2021 Jun;28:100275. doi: 10.1016/j.jcpo.2021.100275. Epub 2021 Feb 16. [Also as PMID: 35559905]
    • Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico.
    • Blazer KR, Chavarri-Guerra Y, Villarreal Garza C, Nehoray B, Mohar A, Daneri-Navarro A, Del Toro A, Aguilar D, Arteaga J, Álvarez RM, Mejia R, Herzog J, Castillo D, Fernandez M, Weitzel JN.
    • JCO Glob Oncol. 2021 Jun;7:992-1002. doi: 10.1200/GO.20.00587.
    • Genetic counselor approaches to BRCA1/2 direct-to-consumer genetic testing results.
    • Burke S, Mork M, Qualmann K, Woodson A, Jin Ha M, Arun B, Kaulfus M.
    • J Genet Couns. 2021 Jun;30(3):803-812. doi: 10.1002/jgc4.1380. Epub 2021 Feb 6.
    • Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort.
    • Verdial FC, Bartek MA, Anderson BO, Javid SH.
    • J Surg Oncol. 2021 Jun;123(7):1504-1512. doi: 10.1002/jso.26372. Epub 2021 Mar 18.
    • Motivations and barriers to pursue cancer genomic testing: A systematic review.
    • Smith-Uffen M, Bartley N, Davies G, Best M.
    • Patient Educ Couns. 2021 Jun;104(6):1325-1334. doi: 10.1016/j.pec.2020.12.024. Epub 2020 Dec 25.
    • Review
    • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.
    • Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin JR, Laberge M, Gekas J, Hébert J, Pomey MP, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Bouchard K, Rhéaume J, Boisvert K, Brousseau C, Castonguay L, Fortier S, Gosselin I, Lachapelle P, Lavoie S, Poirier B, Renaud MC, Ruizmangas MG, Sebastianelli A, Roy S, Côté M, Racine MM, Roy MC, Côté N, Brisson C, Charette N, Faucher V, Leblanc J, Dubeau MÈ, Plante M, Desbiens C, Beaumont M, Simard J, Nabi H.
    • Cancers (Basel). 2021 May 31;13(11):2729. doi: 10.3390/cancers13112729.
    • Genetic Testing Challenges in Oncology: Immigrant Mislabeled as BRCA-Positive, Regrets Ovary Removal.
    • Ray T.
    • Precision Oncology News. Diagnostics. Molecular Diagnostics. 2021 May 28.
    • Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    • Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R.
    • Int J Mol Sci. 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.
    • Health system interventions to integrate genetic testing in routine oncology services: A systematic review.
    • O'Shea R, Taylor N, Crook A, Jacobs C, Jung Kang Y, Lewis S, Rankin NM.
    • PLoS One. 2021 May 19;16(5):e0250379. doi: 10.1371/journal.pone.0250379.
    • Next-Generation Sequencing-Based Biomarkers in Breast Cancer.
    • Han W, Lim W.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:323-335. doi: 10.1007/978-981-32-9620-6_16.
    • Review, eBook chapter
    • The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
    • Gráf A, Enyedi MZ, Pintér L, Kriston-Pál É, Jaksa G, Bálind Á, Ezer É, Horváth P, Sükösd F, Kiss E, Haracska L.
    • Cancers (Basel). 2021 May 13;13(10):2354. doi: 10.3390/cancers13102354.
    • Frequency of CDH1 Germline Mutations in Non-Gastric Cancers.
    • Massari G, Magnoni F, Favia G, Peradze N, Veronesi P, La Vecchia C, Corso G.
    • Cancers (Basel). 2021 May 12;13(10):2321. doi: 10.3390/cancers13102321.
    • Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network.
    • Fan X, Wynn J, Shang N, Liu C, Fedotov A, Hallquist MLG, Buchanan AH, Williams MS, Smith ME, Hoell C, Rasmussen-Torvik LJ, Peterson JF, Wiesner GL, Murad AM, Jarvik GP, Gordon AS, Rosenthal EA, Stanaway IB, Crosslin DR, Larson EB, Leppig KA, Henrikson NB, Williams JL, Li R, Hebbring S, Weng C, Shen Y, Crew KD, Chung WK.
    • JNCI Cancer Spectr. 2021 May 8;5(4):pkab044. doi: 10.1093/jncics/pkab044.
    • One of the Biggest Healthcare Frauds Ever Is Still Ongoing — Cancer Genetic Testing Scams.
    • Mulcahy N.
    • Medscape Oncology. 2021 May 4.
    • Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    • Gamble CR, Huang Y, Wright JD, Hou JY.
    • Gynecol Oncol. 2021 May 3:S0090-8258(21)00345-0. doi: 10.1016/j.ygyno.2021.04.025. Epub ahead of print.
    • Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
    • Zhang R, Gao P, Han Y, Zhang R, Tan P, Zhou L, Zhang J, Xie J, Li J.
    • Breast Cancer. 2021 May;28(3):672-683. doi: 10.1007/s12282-020-01204-x. Epub 2021 Jan 5.
    • Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre.
    • Beard C, Monohan K, Cicciarelli L, James PA.
    • Eur J Hum Genet. 2021 May;29(5):872-880. doi: 10.1038/s41431-021-00848-3. Epub 2021 Mar 15.
    • Screening High-Risk Women Veterans for Breast Cancer.
    • Park YA, Keller A, Hsu TM, Bidassie B, Venne V, Hawley D, Hoffman-Högg L, Heron B, Colonna S, Aggarwal A.
    • Fed Pract. 2021 May;38(Suppl 2):S35-S41. doi: 10.12788/fp.0122.
    • The role of the genetic testing industry in patient education of hereditary cancer: An observational study assessing the quality of patient education videos.
    • Greenberg DC, Kamara D, Tatsugawa Z, Mendoza M, Pineda E, Holschneider CH, Zakhour M.
    • Gynecol Oncol. 2021 May;161(2):516-520. doi: 10.1016/j.ygyno.2021.02.013. Epub 2021 Feb 19.
    • Hérédité et cancer [Heredity and cancer].
    • Docampo E, Martin M, Gangolf M, Harvengt J, Bulk S, Segers K, Leroi N, Lete C, Palmariciotti V, Freire Chadrina V, Lambert F, Bours V.
    • Rev Med Liege. 2021 May;76(5-6):327-336. French.
    • Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females.
    • Chu AT, Tse DM, Suen DTK, Kwong A.
    • J Community Genet. 2021 Apr 30. doi: 10.1007/s12687-021-00518-3. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: BRCA1-Positive Patient Told Paternal Cancer Risk Unimportant.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Apr 29.
    • Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
    • Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghate SR.
    • Future Oncol. 2021 Apr 28. doi: 10.2217/fon-2021-0153. Epub ahead of print.
    • Value of a genetics clinic evaluation in identifying women at risk for hereditary breast-ovarian cancer syndrome.
    • Hinshaw JC, Zhao LP, Brimm JE, Payne TH, Hisama FM.
    • J Genet Couns. 2021 Apr 21. doi: 10.1002/jgc4.1425. Epub ahead of print.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada.
    • Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR.
    • Cancers (Basel). 2021 Apr 15;13(8):1894. doi: 10.3390/cancers13081894.
    • Hunting for Hereditary Cancers.
    • May M.
    • Clinical OMICs. 2021 Apr 9. Mar/Apr 2021; 8(2).
    • A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care.
    • McCuaig JM, Thain E, Malcolmson J, Keshavarzi S, Armel SR, Kim RH.
    • Curr Oncol. 2021 Apr 8;28(2):1459-1471. doi: 10.3390/curroncol28020138.
    • Controversies in Hereditary Cancer Management.
    • AlHilli MM, Pederson HJ.
    • Obstet Gynecol. 2021 Apr 8. doi: 10.1097/AOG.0000000000004364. Epub ahead of print.
    • BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing.
    • Szczerba E, Kaminska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska MA.
    • Genes (Basel). 2021 Apr 2;12(4):519. doi: 10.3390/genes12040519.
    • Genetic Counseling Clinic at AIIMS (New Delhi).
    • Maitra D, Manek P, Gupta N, Srivastava A.
    • Indian J Surg Oncol. 2021 Apr;12(Suppl 1):30-33. doi: 10.1007/s13193-020-01054-1. Epub 2020 Apr 4.
    • Breast cancer polygenic risk scores in the clinical cancer genetic counseling setting: Current practices and impact on patient management.
    • McGuinness M, Fassi E, Wang C, Hacking C, Ellis V.
    • J Genet Couns. 2021 Apr;30(2):588-597. doi: 10.1002/jgc4.1347. Epub 2020 Oct 30.
    • Wer braucht eine genetische Beratung? [Who must be referred for genetic counseling?].
    • Monnerat C, Dobbie M.
    • Ther Umsch. 2021 Apr;78(3):145-148. German. doi: 10.1024/0040-5930/a001251.
    • Review, [Article in German]
    • Genetic Testing Challenges in Oncology: BRCA1-Positive Breast Cancer Patient Told She's Negative.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Mar 26.

    Blog post: Genetic Testing Challenges in Oncology: BRCA1-Positive Breast Cancer Patient Told She’s Negative. (My Gene Counsel)

    • O'Neal Comprehensive Cancer Center, My Gene Counsel Partner for Digital Genetic Testing Support.
    • [No author given]
    • Precision Oncology News. Technology. 2021 Mar 26.
    • Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
    • Desai NV, Yadav S, Batalini F, Couch FJ, Tung NM.
    • Cancer. 2021 Mar 15;127(6):828-833. doi: 10.1002/cncr.33305. Epub 2020 Nov 4.
    • Commentary
    • Variations in breast cancer surgical treatment and timing: determinants and disparities.
    • Dankwa-Mullan I, George J, Roebuck MC, Tkacz J, Willis VC, Reyes F, Arriaga YE.
    • Breast Cancer Res Treat. 2021 Mar 10. doi: 10.1007/s10549-021-06155-1. Epub ahead of print.
    • Clinical and community genetics services in the Dutch Caribbean.
    • Verberne EA, Ecury-Goossen GM, Manshande ME, Ponson-Wever M, de Vroomen M, Tilanus M, Mannens MMAM, Henneman L, van Haelst MM.
    • J Community Genet. 2021 Mar 10:1-5. doi: 10.1007/s12687-021-00515-6. Epub ahead of print.

    Duplicate:

    Clinical and community genetics services in the Dutch Caribbean.

    • Foundation Medicine, InformedDNA Partner to Expand Genetic Counseling for Cancer Patients.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 9.
    • Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives.
    • Bennett S, Alexander E, Fraser H, Bowers N, Wallace A, Woodward ER, Lalloo F, Quinn AM, Huang S, Schlecht H, Evans DG.
    • Eur J Hum Genet. 2021 Mar 2. doi: 10.1038/s41431-021-00817-w. Epub ahead of print.
    • The Importance of Learning Your Pancreatic Cancer Risk When Cancer Runs in Your Family.
    • Coffin T.
    • FORCE. Blog. 2021 Mar 2.
    • Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 2.
    • Genetic Testing Challenges in Oncology: Forged Genetic Test Report Leads to Incorrect Management.
    • Ray T.
    • Precision Oncology News. Diagnostics. 2021 Mar 1.
    • Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia.
    • Hallenstein LG, Sorensen C, Hodgson L, Wen S, Westhuyzen J, Hansen C, Last ATJ, Amalaseelan JV, Salindera S, Ross W, Spigelman AD, Shakespeare TP, Aherne NJ.
    • Hered Cancer Clin Pract. 2021 Feb 26;19(1):19. doi: 10.1186/s13053-021-00176-z.
    • Barriers and Facilitators to Genetic Service Delivery Models: Scoping Review.
    • Raspa M, Moultrie R, Toth D, Haque SN.
    • Interact J Med Res. 2021 Feb 25;10(1):e23523. doi: 10.2196/23523.
    • Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea.
    • Hong J, Lee J, Kwon M, Kim JY, Kim JW, Ahn JS, Im YH, Park YH.
    • Diagnostics (Basel). 2021 Feb 22;11(2):370. doi: 10.3390/diagnostics11020370.
    • Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    • Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.
    • Eur J Cancer. 2021 Feb 22;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub ahead of print.
    • Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    • Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.
    • Eur J Cancer. 2021 Feb 21;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub ahead of print.
    • Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
    • Kim SH, Hwang HK, Lee WJ, Kang CM.
    • Pancreatology. 2021 Feb 14:S1424-3903(21)00057-0. doi: 10.1016/j.pan.2021.02.007. Epub ahead of print.
    • Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer.
    • Ripperger T, Evans D, Malkin D, Kratz CP.
    • Fam Cancer. 2021 Feb 12. doi: 10.1007/s10689-021-00228-2. Epub ahead of print.
    • Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study.
    • Oosthuizen J, Kotze MJ, Van Der Merwe N, Myburgh EJ, Bester P, van der Merwe NC.
    • Front Oncol. 2021 Feb 12;10:619469. doi: 10.3389/fonc.2020.619469.
    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer.
    • Moradian MM, Babikyan DT, Markarian S, Petrosyan JG, Avanesian N, Arutunyan T, Sarkisian TF.
    • Hum Genome Var. 2021 Feb 9;8(1):9. doi: 10.1038/s41439-021-00140-2.
    • Gene Screenings Hold Disease Clues, but Unexplained Anomalies Often Raise Fears.
    • Bennett C.
    • KHN [Kaiser Health News]. 2021 Feb 9.

    Press: Ambiguous genetic test results can be unsettling. Worse, they can lead to needless surgeries. (Washington Post)

    Press: My Gene Counsel Quoted in Washington Post and Kaiser Health News. (My Gene Counsel)

    • Downstream Revenue Generated by a Cancer Genetic Counselor.
    • Mauer CB, Reys BD, Hall RE, Campbell CL, Pirzadeh-Miller SM.
    • JCO Oncol Pract. 2021 Feb 8:OP2000464. doi: 10.1200/OP.20.00464. Epub ahead of print.
    • Implementing genomic screening in diverse populations.
    • Abul-Husn NS, Soper ER, Braganza GT, Rodriguez JE, Zeid N, Cullina S, Bobo D, Moscati A, Merkelson A, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2021 Feb 5;13(1):17. doi: 10.1186/s13073-021-00832-y.
    • Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
    • Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez EA, Lizaola-Mayo B, Lehrer M, Thorpe CS, Yu NY, Esplin ED, Nussbaum RL, Sharp RR, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce AH, Bekaii-Saab TS, Sekulic A, Stewart AK.
    • JAMA Oncol. 2021 Feb 1;7(2):230-237. doi: 10.1001/jamaoncol.2020.6252. Erratum in: JAMA Oncol. 2021 Feb 1;7(2):312.

    Letter, Comment:

    Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.

    Letter, Comment:

    Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.

    Letter, Reply:

    Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer-Reply.

    • Initiatives to Scale Up and Expand Reach of Cancer Genomic Services Outside of Specialty Clinical Settings: A Systematic Review.
    • Guan Y, McBride CM, Rogers H, Zhao J, Allen CG, Escoffery C.
    • Am J Prev Med. 2021 Feb;60(2):e85-e94. doi: 10.1016/j.amepre.2020.08.029. Epub 2020 Nov 7.
    • Review
    • Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
    • Lattimore V, Parsons MT, Spurdle AB, Pearson J, Lehnert K, Sullivan J, Lintott C, Bawden S, Morrin H, Robinson B, Walker L.
    • Breast Cancer Res Treat. 2021 Feb;185(3):583-590. doi: 10.1007/s10549-020-05986-8. Epub 2020 Oct 28.
    • Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
    • Loeb S, Giri VN.
    • Eur Urol Oncol. 2021 Feb;4(1):1-9. doi: 10.1016/j.euo.2020.11.011. Epub 2020 Dec 31.

    Commentary:

    Streamlining Germline Genetic Testing in Prostate Cancer.

    Commentary:

    Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.

    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • The impact of the number of tests presented and a provider recommendation on decisions about genetic testing for cancer risk.
    • Schwartz MLB, Klein WMP, Erby LAH, Smith CH, Roter DL.
    • Patient Educ Couns. 2021 Feb;104(2):265-275. doi: 10.1016/j.pec.2020.09.020. Epub 2020 Sep 18.
    • Economic impact of multigene panel testing for hereditary breast and ovarian cancer.
    • Byfield SD, Wei H, DuCharme M, Lancaster JM.
    • J Comp Eff Res. 2021 Jan 25. doi: 10.2217/cer-2020-0192. Epub ahead of print.
    • Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening.
    • Kadri MSN, Patel KM, Bhargava PA, Shah FD, Badgujar NV, Tarapara BV, Patel PS, Shaikh MI, Shah K, Patel A, Pandya S, Vora H, Joshi CG, Joshi MN.
    • Front Oncol. 2021 Jan 21;10:568786. doi: 10.3389/fonc.2020.568786.
    • BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update.
    • Savanevich A, Ashuryk O, Cybulski C, Lubinski J, Gronwald J.
    • Hered Cancer Clin Pract. 2021 Jan 21;19(1):13. doi: 10.1186/s13053-021-00169-y.
    • Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences.
    • Velthuizen ME, van der Luijt RB, de Vries BJ, Koudijs MJ, Bleiker EMA, Ausems MGEM.
    • Hered Cancer Clin Pract. 2021 Jan 19;19(1):9. doi: 10.1186/s13053-021-00166-1.
    • Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
    • Liu Y, Wang H, Wang X, Liu J, Li J, Wang X, Zhang Y, Bai Z, Zhou Q, Wu Y, Shen Y, Weng X, Liu F, Guo J, Di L, Gires O, Zhang Z, Chen Y, Wang H.
    • J Hematol Oncol. 2021 Jan 18;14(1):18. doi: 10.1186/s13045-020-01010-0.
    • Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
    • Shani H, Bernstein-Molho R, Laitman Y, Netzer I, Friedman E.
    • Breast Cancer Res Treat. 2021 Jan 15. doi: 10.1007/s10549-020-06084-5. Epub ahead of print.
    • Case report
    • Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
    • McAlarnen L, Stearns K, Uyar D.
    • Appl Clin Genet. 2021 Jan 14;14:1-9. doi: 10.2147/TACG.S245021.
    • FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study.
    • Giornelli G, Gallardo D, Hegg R, Abuin GG, La Vega M, Lim-Law M, Caceres V, Trujillo L, Pilar Estevez-Diz MD, Pacheco C, Sganga L, Goncalves S.
    • Future Oncol. 2021 Jan 8. doi: 10.2217/fon-2020-1152. Epub ahead of print.
    • Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
    • Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN.
    • J Genet Couns. 2021 Jan 7. doi: 10.1002/jgc4.1374. Epub ahead of print.
    • Guidelines
    • Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness.
    • Zhao Y, Weroha SJ, Goode EL, Liu H, Wang C.
    • BMC Med Inform Decis Mak. 2021 Jan 6;21(1):3. doi: 10.1186/s12911-020-01364-y.
    • Comprehensive evaluation of BRCA1/2 variant interpretation ability among laboratories in China.
    • Shao K, Wang R, Qu S, Zhang W, Yu T, Cao B, Dai P, Zhu A, Zhang J, Wang J, Wang L, Zhu S, Wu K, Yang X, Chang X, Chen F, Huang J.
    • J Med Genet. 2021 Jan 4:jmedgenet-2020-107360. doi: 10.1136/jmedgenet-2020-107360. Epub ahead of print.
    • BRCA testing and outcomes in women with breast cancer.
    • Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06038-x. Epub ahead of print.
    • Increased ease of access to genetic counseling for low-income women with breast cancer using a point of care screening tool.
    • Rao SK, Thomas KA, Singh R, Biltibo E, Lammers PE, Wiesner GL.
    • J Community Genet. 2021 Jan 3. doi: 10.1007/s12687-020-00499-9. Epub ahead of print.
    • My Gene Counsel and Genomet Announce Product Partnership to Transform Cancer Care Around the Globe.
    • [No author given]
    • My Gene Counsel. Press Releases. 2020 Dec 29.
    • My Gene Counsel, Genomet Develop Decision Support Solution for Precision Cancer Care.
    • [No author given]
    • Precision Oncology News. 2020 Dec 29.
    • Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel.
    • Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D.
    • Cancer Prev Res (Phila). 2020 Dec 22:canprevres.0411.2020. doi: 10.1158/1940-6207.CAPR-20-0411. Epub ahead of print.
    • Examining the uptake of predictive BRCA testing in the UK; findings and implications.
    • Martin AP, Downing J, Collins B, Godman B, Alfirevic A, Greenhalgh KL, Pirmohamed M.
    • Eur J Hum Genet. 2020 Dec 16. doi: 10.1038/s41431-020-00783-9. Epub ahead of print.
    • Germline TP53 Testing in Breast Cancers: Why, When and How?
    • Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T.
    • Cancers (Basel). 2020 Dec 14;12(12):3762. doi: 10.3390/cancers12123762.
    • BRCA testing delay during the COVID-19 pandemic: How to act?
    • Minucci A, Scambia G, De Bonis M, De Paolis E, Santonocito C, Fagotti A, Capoluongo E, Concolino P, Urbani A.
    • Mol Biol Rep. 2020 Dec 12. doi: 10.1007/s11033-020-06060-8. Epub ahead of print.
    • New Approach for Risk Estimation Algorithms of BRCA1/2 Negativeness Detection with Modelling Supervised Machine Learning Techniques.
    • Yazici H, Odemis DA, Aksu D, Erdogan OS, Tuncer SB, Avsar M, Kilic S, Turkcan GK, Celik B, Aydin MA.
    • Dis Markers. 2020 Dec 9;2020:8594090. doi: 10.1155/2020/8594090.
    • DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
    • Armstrong N, Quek RG, Ryder S, Ross J, Titas Buksnys, Forbes C, Fox KM, Castro E.
    • Future Oncol. 2020 Dec 2. doi: 10.2217/fon-2020-0569. Epub ahead of print.
    • Review
    • Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.
    • Printz C.
    • Cancer. 2020 Dec 1;126(23):5007. doi: 10.1002/cncr.33302.

    Original research:

    Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.

    • Current practices on genetic testing in ovarian cancer.
    • Fostira F, Papadimitriou M, Papadimitriou C.
    • Ann Transl Med. 2020 Dec;8(24):1703. doi: 10.21037/atm-20-1422.
    • Ovarian cancer risk assessment in the era of next-generation sequencing.
    • Bonadio RC, Crespo JR, Estevez-Diz MDP.
    • Ann Transl Med. 2020 Dec;8(24):1704. doi: 10.21037/atm-20-1582.
    • Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study.
    • Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S.
    • Cancers (Basel). 2020 Nov 27;12(12):3543. doi: 10.3390/cancers12123543.
    • Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
    • Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY.
    • J Genet Couns. 2020 Nov 27. doi: 10.1002/jgc4.1360. Epub ahead of print.
    • Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
    • Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, Nikopensius T, Esko T, Metspalu A, Padrik P, Tõnisson N.
    • Eur J Hum Genet. 2020 Nov 23. doi: 10.1038/s41431-020-00760-2. Epub ahead of print.
    • BRCA gene testing in women with high-grade serous ovarian carcinoma.
    • Kansu B, Gardner J, Price-Tate R, Murch O, Murray A.
    • J Obstet Gynaecol. 2020 Nov 23:1-4. doi: 10.1080/01443615.2020.1820466. Epub ahead of print.
    • Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    • Rana HQ, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes SM, Fekrmandi F, Vatnick D, Matulonis UA, Garber JE, Wright AA.
    • Gynecol Oncol. 2020 Nov 21:S0090-8258(20)34111-1. doi: 10.1016/j.ygyno.2020.11.003. Epub ahead of print.
    • Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
    • Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Mil Med. 2020 Nov 18:usaa485. doi: 10.1093/milmed/usaa485. Epub ahead of print.
    • Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective.
    • [No author given]
    • Clinical OMICs. Molecular Dx. 2020 Nov 17.

    Original research:

    Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.

    • Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
    • Benusiglio PR, Korenbaum C, Vibert R, Ezenfis J, Geoffron S, Paul C, Richard S, Byrde V, Lejeune M, Guillerm E, Basset N, Lotz JP, Chabbert-Buffet N, Gligorov J, Coulet F.
    • Eur J Med Genet. 2020 Nov 10;63(12):104098. doi: 10.1016/j.ejmg.2020.104098. Epub ahead of print.
    • Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018.
    • Guo F, Scholl M, Fuchs EL, Wong R, Kuo YF, Berenson AB.
    • JAMA Netw Open. 2020 Nov 2;3(11):e2024358. doi: 10.1001/jamanetworkopen.2020.24358.

    Commentary:

    Time for BRCA Testing Among Women 65 Years or Older in the United States.

    • NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of BRCA-Negative Cases.
    • Zanti M, Loizidou MA, Michailidou K, Pirpa P, Machattou C, Marcou Y, Kyriakou F, Kakouri E, Tanteles GA, Spanou E, Spyrou GM, Kyriacou K, Hadjisavvas A.
    • Cancers (Basel). 2020 Oct 27;12(11):3140. doi: 10.3390/cancers12113140.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • The factors associated with distress a minimum of six months after BRCA1/2 confirmation: A systematic review.
    • Butler E, Collier S, Hevey D.
    • J Psychosoc Oncol. 2020 Oct 22:1-27. doi: 10.1080/07347332.2020.1836109. Epub ahead of print.
    • Review
    • Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting.
    • Anderson JL, Kruisselbrink TM, Lisi EC, Hughes TM, Steyermark JM, Winkler EM, Berg CM, Vierkant RA, Gupta R, Ali AH, Faubion SS, Aoudia SL, McAllister TM, Farrugia G, Stewart AK, Lazaridis KN.
    • Mayo Clin Proc. 2020 Oct 21:S0025-6196(20)31119-8. doi: 10.1016/j.mayocp.2020.08.051. Epub ahead of print.
    • Germline testing for homologous recombination repair genes - opportunities and challenges.
    • Hirsch S, Gieldon L, Sutter C, Dikow N, Schaaf CP.
    • Genes Chromosomes Cancer. 2020 Oct 20. doi: 10.1002/gcc.22900. Epub ahead of print.
    • Review
    • The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.
    • Mogaka JJO, Chimbari MJ.
    • PLoS One. 2020 Oct 14;15(10):e0240585. doi: 10.1371/journal.pone.0240585.
    • Should You Recommend Direct-to-Consumer Genetic Testing for This Patient? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    • Smetana GW, Vassy JL, Hofstatter E, Libman H.
    • Ann Intern Med. 2020 Oct 6;173(7):563-571. doi: 10.7326/M20-5419.
    • Case report
    • Knowledge and Attitudes About Genetic Testing Among Black and White Women with Breast Cancer.
    • McCall MK, Ibikunle S, Murphy Y, Hunter K, Rosenzweig MQ.
    • J Racial Ethn Health Disparities. 2020 Oct 6. doi: 10.1007/s40615-020-00878-5. Epub ahead of print.
    • Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    • Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, Hassen D, Snyder SR, Graves JA, Peterson JF, Williams MS, Veenstra DL.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2022874. doi: 10.1001/jamanetworkopen.2020.22874.

    Press: Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective. (Clinical OMICs)

    • Was ist neu bei der Diagnostik und Therapie des Mammakarzinoms? – Aktuelle Standards in der Behandlung von Brustkrebs [Breast cancer - state of the art - Short overview of the current standard of treatment].
    • Albert A, Stüber T, Bauer J, Wöckel A.
    • Dtsch Med Wochenschr. 2020 Oct;145(20):1460-1463. German. doi: 10.1055/a-1026-3620. Epub 2020 Oct 6.
    • Review, [Article in German]
    • Genetic testing approaches for hereditary breast cancer: Perspectives from a private diagnostic laboratory.
    • Smith DC, Gardiner SA, Conradie M, Gerber J, Loubser F.
    • S Afr Med J. 2020 Sep 30;110(10):988-992. doi: 10.7196/SAMJ.2020.v110i10.14709.
    • Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
    • Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
    • Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.
    • Cancer Predisposition Genes in Cancer-Free Families.
    • Zheng G, Catalano C, Bandapalli OR, Paramasivam N, Chattopadhyay S, Schlesner M, Sijmons R, Hemminki A, Dymerska D, Lubinski J, Hemminki K, Försti A.
    • Cancers (Basel). 2020 Sep 27;12(10):2770. doi: 10.3390/cancers12102770.
    • Bioethics and healthcare policies. The benefit of using genetic tests of BRCA 1 and BRCA 2 in elderly patients.
    • Fonseca V, Caeiro J.
    • Int J Health Plann Manage. 2020 Sep 25. doi: 10.1002/hpm.3072. Epub ahead of print.
    • Commentary
    • Impact of Numeracy Preferences on Information Needs for Genome Sequencing Results.
    • Albrechtsen RD, Goodman MS, Bathar J, Kaphingst KA.
    • Patient Educ Couns. 2020 Sep 25:S0738-3991(20)305309. doi: 10.1016/j.pec.2020.09.032. Epub ahead of print.
    • "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
    • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Support Care Cancer. 2020 Sep 25. doi: 10.1007/s00520-020-05779-1. Epub ahead of print.
    • Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China.
    • Wu H, Xu B, Gao Q, Zhou X, Shao J, Liang Z, Ma D.
    • Mol Diagn Ther. 2020 Sep 24. doi: 10.1007/s40291-020-00489-0. Epub ahead of print.
    • Screening of germline mutations in young Rwandan patients with breast cancers.
    • Uyisenga JP, Segers K, Lumaka AZ, Mugenzi P, Fasquelle C, Boujemila B, Josse C, Mutesa L, Bours V.
    • Mol Genet Genomic Med. 2020 Sep 22:e1500. doi: 10.1002/mgg3.1500. Epub ahead of print.
    • Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
    • Green RF, Kumerow MT, Rodriguez JL, Addie S, Beachy SH, Senier L.
    • Public Health Genomics. 2020 Sep 17:1-12. doi: 10.1159/000510336. Epub ahead of print.

    Original research:

    Proposed outcomes measures for state public health genomic programs.

    • Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    • Alberty-Oller JJ, Weltz S, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E.
    • Ann Surg Oncol. 2020 Sep 11. doi: 10.1245/s10434-020-09123-z. Epub ahead of print.
    • NCCN Updates Guidelines Advising Against Using Polygenic Risk Scores Outside of Clinical Trials.
    • [No author given]
    • GenomeWeb. Diagnostics. 2020 Sep 10.
    • BRCA1/2 Testing in Massachusetts Among Women With Private Insurance or Medicaid, 2011-2015.
    • Pace LE, Baum CF, Horvath K, Raja SC, Cohen J, Hawkins SS.
    • Med Care. 2020 Sep 10. doi: 10.1097/MLR.0000000000001405. Epub ahead of print.
    • Relaunched Canadian BRCA1/2 Screening Project Aims to ID High-Risk Carriers, Intervene Early.
    • Anderson A.
    • Precision Oncology News. 2020 Sep 8.
    • News
    • Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
    • Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Sep 6:ijgc-2020-001556. doi: 10.1136/ijgc-2020-001556. Epub ahead of print.
    • Review
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
    • Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes.
    • [No author given]
    • Precision Oncology News. 2020 Sep 3.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
    • Ataseven B, Tripon D, Rhiem K, Harter P, Schneider S, Heitz F, Baert T, Traut A, Pauly N, Ehmann S, Plett H, Schmutzler RK, du Bois A.
    • Geburtshilfe Frauenheilkd. 2020 Sep;80(9):932-940. doi: 10.1055/a-1222-0042. Epub 2020 Sep 2.
    • Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review.
    • Chung JS, Morgan TM, Hong SK.
    • Prostate Int. 2020 Sep;8(3):99-106. doi: 10.1016/j.prnil.2020.09.001. Epub 2020 Sep 14.
    • Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
    • Yoshida R.
    • Breast Cancer. 2020 Aug 29. doi: 10.1007/s12282-020-01148-2. Epub ahead of print.
    • Strategies to enhance identification of hereditary breast cancer gene carriers.
    • Reid S, Spalluto LB, Pal T.
    • Expert Rev Mol Diagn. 2020 Aug 28. doi: 10.1080/14737159.2020.1816829. Epub ahead of print.
    • Germline mutations and prostate cancer: is it time to change treatment algorithms?
    • Telvizian T, Mukherji D.
    • Chin Clin Oncol. 2020 Aug 27:cco-19-207. doi: 10.21037/cco-19-207. Epub ahead of print.
    • Study: Among women with breast cancer, who should have genetic testing for an inherited mutation?
    • [No author given]
    • FORCE. XRAYS. 2020 Aug 27.

    Original research:

    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

    • Early-onset breast cancer in a woman with a germline mobile element insertion resulting in BRCA2 disruption: a case report.
    • Deuitch N, Li ST, Courtney E, Shaw T, Dent R, Tan V, Yackowski L, Torene R, Berkofsky-Fessler W, Ngeow J.
    • Hum Genome Var. 2020 Aug 25;7:24. doi: 10.1038/s41439-020-00111-z.
    • The management of BRCA1 and BRCA2 carriers in Singapore.
    • Chiang J, Ngeow J.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-104. doi: 10.21037/cco-20-104. Epub ahead of print.
    • Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    • Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.
    • Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.
    • Qin Z, Kuok CN, Dong H, Jiang L, Zhang L, Guo M, Leong HK, Wang L, Meng G, Wang SM.
    • J Med Genet. 2020 Aug 17:jmedgenet-2020-107181. doi: 10.1136/jmedgenet-2020-107181. Epub ahead of print.
    • Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
    • Jiang Y, Tian T, Yu C, Zhou W, Yang J, Wang Y, Wen Y, Chen J, Dai J, Jin G, Ma H, Shen H, Hu Z.
    • Biomed Res Int. 2020 Aug 15;2020:6739823. doi: 10.1155/2020/6739823.
    • Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection.
    • Paradiso AV, Patruno M, Digennaro M, Tommasi S, Pilato B, Argentiero A, Brunetti O, Silvestris N.
    • Front Oncol. 2020 Aug 12;10:1292. doi: 10.3389/fonc.2020.01292.
    • Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
    • Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC.
    • Cancer Res Treat. 2020 Aug 11. doi: 10.4143/crt.2020.364. Epub ahead of print.
    • Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer.
    • Hartman TR, Demidova EV, Lesh RW, Hoang L, Richardson M, Forman A, Kessler L, Speare V, Golemis EA, Hall MJ, Daly MB, Arora S.
    • Sci Rep. 2020 Aug 11;10(1):13518. doi: 10.1038/s41598-020-70449-5.
    • Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    • El Ansari FZ, Jouali F, Marchoudi N, Bennani MM, Ghailani NN, Barakat A, Fekkak J.
    • BMC Cancer. 2020 Aug 10;20(1):747. doi: 10.1186/s12885-020-07250-0.
    • Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
    • Nguyen-Dumont T, Karpinski P, Sasiadek MM, Akopyan H, Steen JA, Theys D, Hammet F, Tsimiklis H, Park DJ, Pope BJ, Slezak R, Stembalska A, Pesz K, Kitsera N, Siekierzynska A, Southey MC, Myszka A.
    • Genet Res (Camb). 2020 Aug 10;102:e6. doi: 10.1017/S0016672320000075.
    • Pinning Pink: Messages About Hereditary Breast Cancer Risk on Pinterest.
    • Miller CA, Henderson AN, Guidry JPD, McGuire KP, Fuemmeler BF.
    • J Cancer Educ. 2020 Aug 8. doi: 10.1007/s13187-020-01842-x. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk.
    • Ray T.
    • Precision Oncology News. 2020 Aug 6.
    • Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates.
    • Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A.
    • Breast. 2020 Jul 27;53:119-124. doi: 10.1016/j.breast.2020.07.005. Epub ahead of print.
    • Germlines 'Rich Source' of Prostate Cancer Info.
    • O'Rourke K, Giri V.
    • Medscape Oncology. 2020 Jul 21.
    • The contemporary landscape of genetic testing and breast cancer: Emerging issues.
    • Shah PD, Domchek SM.
    • Breast J. 2020 Jul 20. doi: 10.1111/tbj.13968. Epub ahead of print.
    • Review
    • Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.
    • Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, Gaba F, Brentnall A, Duffy S, Cui B, Coelho De Soarez P, Husain Z, Hopper J, Sadique Z, Mukhopadhyay A, Yang L, Berkhof J, Legood R.
    • Cancers (Basel). 2020 Jul 17;12(7):1929. doi: 10.3390/cancers12071929.

    Press: BRCA1/2 Population Screening Predicted to be Cost-Effective in Countries With Different Income Levels (GenomeWeb)

    Commentary:

    Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.

    • Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial.
    • Anderson N, Delavar A, Friedman DN, Joseph V, Mubdi N, Oeffinger KC, Sklar CA, Offit K, Matasar M, Raghunathan N, Antal Z, Straus D, Walsh M, Latham A, Tonorezos ES.
    • J Community Genet. 2020 Jul 16. doi: 10.1007/s12687-020-00478-0. Epub ahead of print.
    • Breast cancer risk assessment and management programs: A practical guide.
    • Sciaraffa T, Guido B, Khan SA, Kulkarni S.
    • Breast J. 2020 Jul 14. doi: 10.1111/tbj.13967. Epub ahead of print.
    • Review
    • Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    • Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR.
    • Eur J Hum Genet. 2020 Jul 10. doi: 10.1038/s41431-020-0692-y. Epub ahead of print.
    • Update on multi-gene panel testing and communication of genetic test results.
    • Reid S, Pal T.
    • Breast J. 2020 Jul 8. doi: 10.1111/tbj.13971. Epub ahead of print.
    • Review
    • Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden.
    • Augustinsson A, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Public Health Genomics. 2020 Jul 8:1-10. doi: 10.1159/000508684. Epub ahead of print.
    • Sequence Now, Later, or Never?
    • Hagemann IS.
    • Clin Chem. 2020 Jul 1;66(7):883-885. doi: 10.1093/clinchem/hvaa053.
    • Case report

    Commentary:

    Commentary on Sequence Now, Later, or Never?

    • Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
    • Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A.
    • JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381.
    • A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results.
    • Scherr CL, Ross Arguedas AA, Getachew-Smith H, Marshall-Fricker C, Shrestha N, Brooks K, Fischhoff B, Vadaparampil ST.
    • Med Decis Making. 2020 Jul;40(5):655-668. doi: 10.1177/0272989X20935864.
    • A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.
    • Starkings R, Shilling V, Jenkins V, Fallowfield L.
    • Breast Cancer Res Treat. 2020 Jun 23. doi: 10.1007/s10549-020-05741-z. Epub ahead of print.
    • Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
    • Simoes Correa-Galendi J, Del Pilar Estevez Diz M, Stock S, Müller D.
    • Appl Health Econ Health Policy. 2020 Jun 15. doi: 10.1007/s40258-020-00599-0. Epub ahead of print
    • Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
    • Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, Kendrick D, Kai J.
    • Fam Cancer. 2020 Jun 11. doi: 10.1007/s10689-020-00188-z. Epub ahead of print.
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    • Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.
    • J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046. Epub ahead of print.

    Press: Cancer Experts Develop Precision Medicine-Based Genetic Testing Framework for Prostate Cancer. (GenomeWeb)

    Press: Consider Genetic Testing in All Metastatic Prostate Cancers. (MedPage Today)

    • "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    • Gill G, Beard C, Storey K, Taylor S, Sexton A.
    • Psychooncology. 2020 Jun 4. doi: 10.1002/pon.5436. Epub ahead of print.
    • Remote Screening Test for Ovarian Cancer Receives Study Validation.
    • [No author given]
    • Clinical OMICs. 2020 Jun 2.
    • Sequencing technology status of BRCA1/2 testing in Latin American Countries.
    • Solano AR, Palmero EI, Delgado L, Carraro DM, Ortíz-López R, Carranza CL, Santamaria C, Cifuentes L, Jara Sosa LE, Toland AE.
    • NPJ Genom Med. 2020 Jun 2;5(1):22. doi: 10.1038/s41525-020-0126-3.
    • Sequencing technology status of BRCA1/2 testing in Latin American Countries.
    • Solano AR, Palmero EI, Delgado L, Carraro DM, Ortíz-López R, Carranza CL, Santamaria C, Cifuentes L, Jara Sosa LE, Toland AE.
    • NPJ Genom Med. 2020 Jun 2;5:22. doi: 10.1038/s41525-020-0126-3.
    • Direct-to-consumer misleading information on cancer risks calls for an urgent clarification of health genetic testing performed by commercial companies.
    • de Pauw A, Schwartz M, Colas C, Golmard L, Stoppa-Lyonnet D.
    • Eur J Cancer. 2020 Jun 1;132:100-103. doi: 10.1016/j.ejca.2020.03.007.
    • Commentary
    • Germline Insights from NGS Somatic Testing: Clinical Challenges and Controversies.
    • Matloff ET, Giri VN, Nowak JA, Sotelo J, Silver DP.
    • Precision Oncology News. Resources: Webinars. 2020 Jun 1.
    • Managing a woman with BRCA mutations? Shared decision-making is key.
    • Schrager S, Torell E, Ledford K, Elezaby M, Barroleit L, Sadowski E.
    • J Fam Pract. 2020 Jun;69(5):237-243.
    • BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic.
    • Minucci A, Scambia G, Santonocito C, Concolino P, Urbani A.
    • Mol Biol Rep. 2020 Jun;47(6):4857-4860. doi: 10.1007/s11033-020-05479-3. Epub 2020 May 9.
    • Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.
    • Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, Kremer ME, Scott DM, O'Hara JS.
    • Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889.
    • Lynch Syndrome Germline Mutations in Breast Cancer: Next Generation Sequencing Case-Control Study of 1,263 Participants.
    • Nikitin AG, Chudakova DA, Enikeev RF, Sakaeva D, Druzhkov M, Shigapova LH, Brovkina OI, Shagimardanova EI, Gusev OA, Gordiev MG.
    • Front Oncol. 2020 May 29;10:666. doi: 10.3389/fonc.2020.00666.
    • Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer.
    • Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP.
    • Radiographics. 2020 May 29:190181. doi: 10.1148/rg.2020190181. Epub ahead of print.
    • Review

    Commentary:

    Invited Commentary: Breast Cancer Risk Assessment and Screening Strategies-What's New?

    • Changing practice: moving to a specialist nurse-led service for BRCA gene testing.
    • Scott N, O'Sullivan J, Asgeirsson K, Macmillan D, Wilson E.
    • Br J Nurs. 2020 May 28;29(10):S6-S13. doi: 10.12968/bjon.2020.29.10.S6.
    • How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.
    • O'Shea R, Rankin NM, Kentwell M, Gleeson M, Salmon L, Tucker KM, Lewis S, Taylor N.
    • Genet Med. 2020 May 28. doi: 10.1038/s41436-020-0838-x. Epub ahead of print.
    • BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
    • Manchana T, Tantbirojn P, Pohthipornthawat N.
    • Gynecol Oncol Rep. 2020 May 27;33:100582. doi: 10.1016/j.gore.2020.100582.
    • Genetic Testing Challenges in Oncology: Missed Mutations Highlight Somatic, Germline Test Difference.
    • Ray T.
    • Precision Oncology News. 2020 May 26.
    • Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers.
    • Pederson HJ, Noss R.
    • Semin Oncol. 2020 May 26:S0093-7754(20)30047-6. doi: 10.1053/j.seminoncol.2020.05.008. Epub ahead of print.
    • Review
    • The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    • Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, Barlow-Stewart K, Kirk J, James P, Scott CL, Williams R, Gamet K, Burke J, Murphy M, Antill YC, Pearn A, Pachter N, Ebzery C, Poplawski N, Friedlander M, Tucker KM; Australian Genetic Testing Mainstreaming Collaborative Group.
    • Gynecol Oncol. 2020 May 22:S0090-8258(20)31028-3. doi: 10.1016/j.ygyno.2020.05.001. Epub ahead of print.
    • Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    • Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.
    • Cancers (Basel). 2020 May 15;12(5):E1241. doi: 10.3390/cancers12051241.
    • Molecular Testing Updates and Impact for Clinical Practice.
    • Slane K.
    • NCCN. Continuing Education. 2020 May 8.
    • Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    • Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.
    • Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.
    • Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    • Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu R, Lee KY, Lindstrom T, Armasu S, Fitz-Gibbon P, Ghosh K, Stan DL, Pruthi S, Neal L, Sandhu N, Rhodes DJ, Klassen C, Peethambaram PP, Haddad TC, Olson JE, Hoskin TL, Goetz MP, Domchek SM, Boughey JC, Ruddy KJ, Couch FJ.
    • J Clin Oncol. 2020 May 1;38(13):1409-1418. doi: 10.1200/JCO.19.02190. Epub 2020 Mar 3.

    Commentary, Research report:

    Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.

    Podcast, Research review: Genetic Testing in Breast Cancer Patients: Striking the Balance Between Over Versus Undertesting. (JCO Podcast. 2020 Mar 11.)

    Research news: Study: Among women with breast cancer, who should have genetic testing for an inherited mutation? (FORCE. XRAYS.)

    • Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    • Demir S, Tozkir H, Gurkan H, Atli EI, Yalcintepe S, Atli E, Sezer YA, Eker D, Tuncbilek N, Tastekin E, Ozen Y, Cicin I.
    • J BUON. 2020 May-Jun;25(3):1337-1347.
    • Evaluation of current genetic testing reports in German-speaking countries with regard to secondary use and future electronic implementation.
    • Radke TF, Patton SJ, Pantazoglou E, Sass J, Thun S.
    • Eur J Hum Genet. 2020 May;28(5):558-566. doi: 10.1038/s41431-020-0586-z. Epub 2020 Feb 13.
    • GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary
    • [No author given.]
    • GenomeWeb. Business & Policy. 2020 Apr 30.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Acceptability and outcomes of multigene panel testing among young Black breast cancer survivors.
    • Conley CC, Garcia JD, Radford C, Reich RR, Monteiro AN, Pal T, Vadaparampil ST.
    • Breast J. 2020 Apr 22. doi: 10.1111/tbj.13848. Epub ahead of print.
    • Commentary
    • Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
    • Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E.
    • Annu Rev Genomics Hum Genet. 2020 Apr 21. doi: 10.1146/annurev-genom-083118-015253. [Epub ahead of print]
    • Mainstream consent programs for genetic counseling in cancer patients: A systematic review.
    • Scheinberg T, Young A, Woo H, Goodwin A, Mahon KL, Horvath LG.
    • Asia Pac J Clin Oncol. 2020 Apr 20. doi: 10.1111/ajco.13334. [Epub ahead of print]
    • Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults.
    • Sutherland N, Espinel W, Grotzke M, Colonna S.
    • J Genet Couns. 2020 Apr 18. doi: 10.1002/jgc4.1278. [Epub ahead of print]
    • Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.
    • Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, Foulkes WD.
    • Sci Rep. 2020 Apr 16;10(1):6491. doi: 10.1038/s41598-020-63100-w.
    • A road map for the future: An exploration of attitudes, perceptions, and beliefs among African Americans to tailor health promotion of cancer-related genetic counseling and testing.
    • Lumpkins CY, Philp A, Nelson KL, Miller LM, Greiner KA.
    • J Genet Couns. 2020 Apr 15. doi: 10.1002/jgc4.1277. [Epub ahead of print]
    • Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 Ovarian Cancer Families: How young is too young?
    • Podwika SE, Jenkins TM, Khokhar JK, Erickson SH, Modesitt SC.
    • Gynecol Oncol Rep. 2020 Apr 7;32:100569. doi: 10.1016/j.gore.2020.100569. eCollection 2020 May.
    • Myriad Genetics BRCA Test to be Reimbursed in Japan.
    • [No author given]
    • GenomeWeb. 2020 Apr 6.
    • Young Women With Breast Cancer: Treatment, Care, and Nursing Implications.
    • Corey B, Smania MA, Spotts H, Andersen M.
    • Clin J Oncol Nurs. 2020 Apr 1;24(2):139-147. doi: 10.1188/20.CJON.139-147.
    • Review
    • Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.
    • Patel AP, Wang M, Fahed AC, Mason-Suares H, Brockman D, Pelletier R, Amr S, Machini K, Hawley M, Witkowski L, Koch C, Philippakis A, Cassa CA, Ellinor PT, Kathiresan S, Ng K, Lebo M, Khera AV.
    • JAMA Netw Open. 2020 Apr 1;3(4):e203959. doi: 10.1001/jamanetworkopen.2020.3959.

    Press: Family History Insufficient to Determine High Risk of Gene-Linked CVD or Cancer. (Clinical OMICs)

    • Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    • Hurry M, Eccleston A, Dyer M, Hoskins P
    • Int J Technol Assess Health Care. 2020 Apr;36(2):104-112. doi: 10.1017/S0266462319003519.
    • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
    • Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD.
    • J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. doi: 10.6004/jnccn.2020.0017.

    Continuing Education course: NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. (NCCN Continuing Education)

    • Public perception of predictive cancer genetic testing and research in Oregon.
    • Alvord TW, Marriott LK, Nguyen PT, Shafer A, Brown K, Stoller W, Volpi JL, Vandehey-Guerrero J, Ferrara LK, Blakesley S, Solomon E, Kuehl H, Palma AJ, Farris PE, Hamman KJ, Cotter M, Shannon J.
    • J Genet Couns. 2020 Mar 27. doi: 10.1002/jgc4.1262. [Epub ahead of print]
    • Genetic Testing for Cancer Predisposition Syndromes in Adolescents and Young Adults (AYAs)
    • Cullinan N, Capra M, McVeigh TP.
    • Curr Genet Med Rep. 2020 Mar 24. doi: 10.1007/s40142-020-00187-7. [Epub ahead of print]
    • Review
    • Germline Genetic Testing, Counseling Move Remote as Pandemic Limits In-Person Care Capacity.
    • Hu C.
    • GenomeWeb. 2020 Mar 24.
    • Prevalence and Spectrum of Pathogenic Germline Variants in Japanese Patients With Early-Onset Colorectal, Breast, and Prostate Cancer.
    • Liu X, Takata S, Ashikawa K, Aoi T, Kosugi S, Terao C, Parrish NF, Matsuda K, Nakagawa H, Kamatani Y, Kubo M, Momozawa Y.
    • JCO Precis Oncol. 2020 Nov [Epub 2020 Mar 24];4:183-191. doi: 10.1200/PO.19.00224.
    • Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia.
    • Sun S, Li ST, Ngeow J.
    • Health Soc Care Community. 2020 Mar 20. doi: 10.1111/hsc.12981. [Epub ahead of print]
    • Genetics/Familial Risk Assessment for Breast Cancer: Controversies and Evolving Principles.
    • Weitzel JN.
    • National Comprehensive Cancer Network. Continuing Education. 2020 Mar 15.
    • DNA tests grow more vital in hereditary breast cancer treatments. They also raise unanswerable questions.
    • Richards SE.
    • Washington Post. Health & Science. 2020 Mar 15.
    • Updated Guideline Moves Genetic Testing Beyond BRCA.
    • Narozniak R.
    • OncologyLive. 2020 Mar 13;21(6).
    • News

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    • Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML.
    • JAMA. 2020 Mar 10;323(10):995-997. doi: 10.1001/jama.2020.0229.

    Press: Inherited Mutations in Postmenopausal Breast Cancer Patients Suggest Genetic Testing Is Warranted. (GenomeWeb)

    Press Release: Older women with breast cancer may benefit from genetic testing. (Stanford Medicine)

    Press: Genetic testing may benefit some postmenopausal women with breast cancer. (Healio)

    • Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation.
    • Monteiro AN, Bouwman P, Kousholt AN, Eccles DM, Millot GA, Masson JY, Schmidt MK, Sharan SK, Scully R, Wiesmüller L, Couch F, Vreeswijk MPG.
    • J Med Genet. 2020 Mar 9. pii: jmedgenet-2019-106368. doi: 10.1136/jmedgenet-2019-106368. [Epub ahead of print]
    • Review
    • Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing.
    • Torrorey-Sawe R, van der Merwe N, Mining SK, Kotze MJ.
    • Front Genet. 2020 Mar 6;11:170. doi: 10.3389/fgene.2020.00170. eCollection 2020.
    • Evaluating Web-Based Direct-to-Consumer Genetic Tests for Cancer Susceptibility.
    • Kilbride MK, Bradbury AR.
    • JCO Precis Oncol. 2020 Mar 5;4:PO.19.00317. doi: 10.1200/PO.19.00317.
    • Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study.
    • Klek S, Heald B, Milinovich A, Ni Y, Abraham J, Mahdi H, Estfan B, Khorana AA, Bolwell BJ, Grivas P, Sohal DPS, Funchain P.
    • JNCI Cancer Spectr. 2020 Mar 5;4(3):pkaa018. doi: 10.1093/jncics/pkaa018.

    Editorial:

    A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing.

    • The Provision of Genetic Testing and Related Services in Quebec, Canada.
    • Unim B, De Vito C, Hagan J, Villari P, Knoppers BM, Zawati M.
    • Front Genet. 2020 Mar 4;11:127. doi: 10.3389/fgene.2020.00127. eCollection 2020.
    • How genomic information is accessed in clinical practice: an electronic survey of UK general practitioners.
    • Evans WRH, Tranter J, Rafi I, Hayward J, Qureshi N.
    • J Community Genet. 2020 Mar 3. doi: 10.1007/s12687-020-00457-5. [Epub ahead of print]
    • Population-based genetic testing for Women's cancer prevention.
    • Evans O, Gaba F, Manchanda R.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Mar 2. pii: S1521-6934(20)30034-1. doi: 10.1016/j.bpobgyn.2020.02.007. [Epub ahead of print]
    • Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome.
    • Breit C, Ablah E, Ward M, Okut H, Tenofsky PL.
    • Am J Surg. 2020 Mar;219(3):430-433. doi: 10.1016/j.amjsurg.2019.10.015. Epub 2019 Oct 11.

    Commentary, Presentation:

    Discussion on: Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome.

    • Should all breast cancer patients get germline genetic testing?
    • Pal T, Domchek S, Graber C
    • Genetics in Medicine. GenePod. 2020 Mar.

    Guidelines:

    Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG).

    Commentary:

    Germline genetic testing for breast cancer: which patients? What genes?

    • Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.
    • Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P.
    • JCO Glob Oncol. 2020 Mar;6:439-452. doi: 10.1200/JGO.19.00170.
    • Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
    • Randall M, Burgess K, Buckingham L, Usha L.
    • J Natl Compr Canc Netw. 2020 Mar;18(3):223-228. doi: 10.6004/jnccn.2019.7378.
    • Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    • Chen B, Zhang G, Li X, Ren C, Wang Y, Li K, Mok H, Cao L, Wen L, Jia M, Li C, Guo L, Wei G, Lin J, Li Y, Zhang Y, Han-Zhang H, Liu J, Lizaso A, Liao N.
    • Aging (Albany NY). 2020 Feb 24;12(4):3140-3155. doi: 10.18632/aging.102783. Epub 2020 Feb 24.
    • Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.
    • Landrith T, Li B, Cass AA, Conner BR, LaDuca H, McKenna DB, Maxwell KN, Domchek S, Morman NA, Heinlen C, Wham D, Koptiuch C, Vagher J, Rivera R, Bunnell A, Patel G, Geurts JL, Depas MM, Gaonkar S, Pirzadeh-Miller S, Krukenberg R, Seidel M, Pilarski R, Farmer M, Pyrtel K, Milliron K, Lee J, Hoodfar E, Nathan D, Ganzak AC, Wu S, Vuong H, Xu D, Arulmoli A, Parra M, Hoang L, Molparia B, Fennessy M, Fox S, Charpentier S, Burdette J, Pesaran T, Profato J, Smith B, Haynes G, Dalton E, Crandall JR, Baxter R, Lu HM, Tippin-Davis B, Elliott A, Chao E, Karam R.
    • NPJ Precis Oncol. 2020 Feb 24;4:4. doi: 10.1038/s41698-020-0109-y. eCollection 2020.
    • The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests: Either Too Narrow or Too Broad.
    • Kilbride MK, Bradbury AR.
    • JAMA. 2020 Feb 19. doi: 10.1001/jama.2019.22504. [Epub ahead of print]

    CME Audio, Interview: The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests: Either Too Narrow or Too Broad. (JAMA Network: JN Learning)

    • Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field.
    • Yanes T, Young MA, Meiser B, James PA.
    • Breast Cancer Res. 2020 Feb 17;22(1):21. doi: 10.1186/s13058-020-01260-3.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement.
    • [No authors listed]
    • Am Fam Physician. 2020 Feb 15;101(4):233-238.

    CME Activity:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    • Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    • Printz C.
    • Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Testing for Breast Cancer Susceptibility Genes.
    • Mangione C, Manchanda R.
    • JAMA Oncology. JN Learning. 2020 Feb 11.
    • Podcast. CME activity.
    • Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    • Angeli D, Salvi S, Tedaldi G.
    • Int J Mol Sci. 2020 Feb 8;21(3). pii: E1128. doi: 10.3390/ijms21031128.
    • Transmission of X-linked Ovarian Cancer: Characterization and Implications.
    • Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH.
    • Diagnostics (Basel). 2020 Feb 7;10(2). pii: E90. doi: 10.3390/diagnostics10020090.
    • Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing.
    • Ray T.
    • GenomeWeb. 2020 Feb 6.
    • BRCA1 & BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    • Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias , Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E.
    • Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32903. [Epub ahead of print]
    • The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients.
    • Therond C, Lanceley A, Gibbon S, Rahman B.
    • Anthropol Med. 2020 Feb 3:1-16. doi: 10.1080/13648470.2019.1663784. [Epub ahead of print]
    • Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.
    • AlHarthi FS, Qari A, Edress A, Abedalthagafi M.
    • NPJ Genom Med. 2020 Feb 3;5:3. doi: 10.1038/s41525-019-0110-y. eCollection 2020.
    • Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk.
    • Underhill ML, Pozzar R, Chung D, Sawhney M, Yurgelun M.
    • J Cancer Educ. 2020 Feb;35(1):194-203. doi: 10.1007/s13187-019-01623-1.
    • Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up.
    • Pellini F, Mirandola S, Granuzzo E, Urbani S, Piccinni Leopardi G, Pollini GP.
    • J Oncol. 2020 Jan 31;2020:3987935. doi: 10.1155/2020/3987935. eCollection 2020.
    • Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway.
    • Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Vamre T, Wangensteen T, Heramb C, Mæhle L.
    • Fam Cancer. 2020 Jan 30. doi: 10.1007/s10689-020-00160-x. [Epub ahead of print]
    • Medicare to Cover Gene Tests in Inherited Breast and Ovarian Cancer.
    • Young KD.
    • Medscape Oncology. 2020 Jan 29.

    Decision Memo: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) (Centers for Medicare & Medicaid Services)

    • Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)
    • Syrek Jensen T, Chin J, Evans MA, Ashby L, Ward A, Rollins J, Li C, Long K.
    • Centers for Medicare & Medicaid Services. 2020 Jan 27.
    • CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients.
    • [No author given]
    • GenomeWeb. 2020 Jan 27.

    Decision Memo: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) (Centers for Medicare & Medicaid Services)

    • Genetic Testing in Prostate Cancer.
    • Sokolova AO, Cheng HH.
    • Curr Oncol Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11912-020-0863-6.
    • Review
    • Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care.
    • Lee SI, Qureshi N, Dutton B, Kai J, Weng S.
    • J Community Genet. 2020 Jan 22. doi: 10.1007/s12687-020-00452-w. [Epub ahead of print]
    • Organizational readiness to implement population-based screening and genetic service delivery for hereditary cancer prevention and control.
    • Knerr S, West KM, Angelo FA.
    • J Genet Couns. 2020 Jan 22. doi: 10.1002/jgc4.1216. [Epub ahead of print]
    • Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
    • Waltz M, Prince AER, O'Daniel JM, Foreman AKM, Powell BC, Berg JS.
    • J Genet Couns. 2020 Jan 22. doi: 10.1002/jgc4.1219. [Epub ahead of print]
    • As Home Genetic Tests Flood Market, Are Physicians Being Left Behind?
    • Miller KD, Domchek S.
    • Medscape Oncology. 2020 Jan 22.
    • Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer.
    • Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK.
    • JNCI Cancer Spectr. 2020 Jan 20;4(2):pkaa002. doi: 10.1093/jncics/pkaa002. eCollection 2020 Apr.
    • Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience.
    • Rummel SK, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Cancers (Basel). 2020 Jan 17;12(1). pii: E234. doi: 10.3390/cancers12010234.
    • Genetic testing for epithelial ovarian cancer.
    • Amin N, Chaabouni N, George A.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Jan 16. pii: S1521-6934(20)30017-1. doi: 10.1016/j.bpobgyn.2020.01.005. [Epub ahead of print]
    • Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer.
    • Zelli V, Compagnoni C, Cannita K, Capelli R, Capalbo C, Di Vito Nolfi M, Alesse E, Zazzeroni F, Tessitore A.
    • High Throughput. 2020 Jan 10;9(1). pii: E1. doi: 10.3390/ht9010001.
    • Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.
    • Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S.
    • J Clin Oncol. 2020 Jan 10:JCO1902010. doi: 10.1200/JCO.19.02010. [Epub ahead of print]
    • Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography.
    • Jones T, Freeman K, Ackerman M, Trivedi MS, Silverman T, Shapiro P, Kukafka R, Crew KD.
    • Oncol Nurs Forum. 2020 Jan 1;47(1):E13-E24. doi: 10.1188/20.ONF.E13-E24.
    • BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update.
    • Saudi Med J. 2020 Jan;41(1):9-17. doi: 10.15537/smj.2020.1.24759.
    • [Learning from My Experience: Outpatient Care for Cancer Multigene Genomic Testing].
    • Aimono E, Iguchi A, Mochida K, Imai M, Hayashi H, Nishihara H.
    • Yakugaku Zasshi. 2020;140(5):667-668. doi: 10.1248/yakushi.19-00217-4.
    • Conference abstract, [Article in Japanese]
    • [Our Treatment Strategy for Patients with Hereditary Breast Cancer Syndrome in Hamamatsu Medical Center].
    • Miyamoto Y, Tochikubo J, Hosokawa Y, Amano K.
    • Yakugaku Zasshi. 2020;140(5):669-671. doi: 10.1248/yakushi.19-00217-5.
    • SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
    • González-Santiago S, Ramón Y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-Del-Alba A; SEOM Hereditary Cancer Working Group.
    • Clin Transl Oncol. 2019 Dec 30. doi: 10.1007/s12094-019-02262-0. [Epub ahead of print]
    • Myriad Data Supports Polygenic Score Value Even in Canonical Mutation Carriers.
    • Ashford M.
    • GenomeWeb. 2019 Dec 27.
    • News
    • Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    • Jorge S, McFaddin AS, Doll KM, Pennington KP, Norquist BM, Bennett RL, Pritchard CC, Swisher EM.
    • Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802-5. doi: 10.1016/j.ygyno.2019.12.010. [Epub ahead of print]
    • Online BRCA1/2 screening in the Australian Jewish community: a qualitative study.
    • Yuen J, Cousens N, Barlow-Stewart K, O'Shea R, Andrews L.
    • J Community Genet. 2019 Dec 26. doi: 10.1007/s12687-019-00450-7. [Epub ahead of print]
    • Ambry Genetics Gains NYS Approval for Paired RNA, DNA Genetic Test.
    • [No author given]
    • GenomeWeb. 2019 Dec 16.

    Original research:

    Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.

    Press: Ambry Genetics Study Finds RNA Testing Can Clarify Role of Variants in Hereditary Cancer Genes. (GenomeWeb)

    • Black Women's Confidence in the Genetic Information Nondiscrimination Act.
    • Sutton AL, Henderson A, Hurtado-de-Mendoza A, Tanner E, Khan M, Quillin J, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Dec 14;16(24). pii: E5112. doi: 10.3390/ijerph16245112.
    • Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG).
    • Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP; Professional Practice and Guidelines Committee.
    • Genet Med. 2019 Dec 13. doi: 10.1038/s41436-019-0712-x. [Epub ahead of print]

    Commentary:

    Germline genetic testing for breast cancer: which patients? What genes?

    Podcast: Should all breast cancer patients get germline genetic testing? (Genetics in Medicine. Genepod. 2020 Mar.)

    Press: Universal Genetic Testing in Breast Cancer May Result in More Harm Than Good, Experts Worry. (GenomeWeb)

    Press: ACMG Suggests Docs Evaluate All Breast Cancer Patients for Genetic Risk Test Suitability. (GenomeWeb)

    • How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis.
    • Brédart A, Dick J, Cano A, Robieux L, De Pauw A, Schmutzler R, Stoppa-Lyonnet D, Dolbeault S, Kop JL.
    • Psychooncology. 2019 Dec 11. doi: 10.1002/pon.5302. [Epub ahead of print]
    • Genetic Testing Challenges in Oncology: False Positive After Testing at Pop-Up Booth.
    • Ray T.
    • Precision Oncology News. 2019 Dec 2.
    • Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
    • [No authors listed]
    • Obstet Gynecol. 2019 Dec;134(6):e143-e149. doi: 10.1097/AOG.0000000000003562.

    Summary:

    Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793.

    • Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing.
    • Cheng X, Gu Z, Sun X, Zhuang Z.
    • Transl Cancer Res. 2019 Dec;8(8):2893-2905. doi: 10.21037/tcr.2019.11.43.
    • Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel.
    • Lerner-Ellis J, Sopik V, Wong A, Lázaro C, Narod SA, Charames GS.
    • J Med Genet. 2019 Nov 29. pii: jmedgenet-2019-106403. doi: 10.1136/jmedgenet-2019-106403. [Epub ahead of print]
    • Update: Genetic causes of hereditary pancreatic cancer: BRCA and beyond
    • [No author given]
    • FORCE. XRAYS. 2019 Nov 26.
    • Myriad Genetics Myriad Wins Japanese Approval for BRACAnalysis to Assess Breast, Ovarian Cancer Risk.
    • [No author given]
    • Clinical Omics. 2019 Nov 21.
    • Myriad Genetics BRACAnalysis Approved by Japanese Regulators.
    • [No author given]
    • GenomeWeb. 2019 Nov 21.
    • As Genetic Testing Access Grows, Travel Time Remains Barrier to In-Person Counseling.
    • Ray T.
    • GenomeWeb. 2019 Nov 20.
    • Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.
    • McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.
    • Int J Gynecol Cancer. 2019 Nov 19. pii: ijgc-2019-000630. doi: 10.1136/ijgc-2019-000630. [Epub ahead of print]
    • Employee Benefits Programs Share Early Experiences Implementing Genetic Testing.
    • Ray T.
    • GenomeWeb. 2019 Nov 15.
    • Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data.
    • Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S, Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, Coppa A, Capalbo C.
    • PeerJ. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019.
    • Ethical Issues in Newborn Sequencing Research: The Case Study of BabySeq.
    • Ross LF, Clayton EW.
    • Pediatrics. 2019 Nov 12. pii: e20191031. doi: 10.1542/peds.2019-1031. [Epub ahead of print]

    Press: Genome Sequencing in Newborns Raises Ethical Issues (NY Times/Reuters)

    • Hereditary prostate cancer - Primetime for genetic testing?
    • Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party.
    • Cancer Treat Rev. 2019 Nov 11;81:101927. doi: 10.1016/j.ctrv.2019.101927. [Epub ahead of print]
    • Review
    • NSGC Panel Divided on Whether Newly Diagnosed Breast Cancer Patients Should Undergo Panel Testing.
    • [No author given]
    • GenomeWeb. 2019 Nov 7.
    • Geisinger MyCode® detects BRCA2 mutation prior to abdominal panniculectomy allowing for DIEP flap breast reconstruction.
    • Kauffman CA.
    • Case Reports Plast Surg Hand Surg. 2019 Nov 6;6(1):145-147. doi: 10.1080/23320885.2019.1684824. eCollection 2019.
    • [What attitude to women at high risk of breast cancer?]
    • Livon D, Moretta J, Noguès C.
    • Presse Med. 2019 Nov 6. pii: S0755-4982(19)30302-1. doi: 10.1016/j.lpm.2019.07.014. [Epub ahead of print]
    • Review, [Article in French]
    • Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    • Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K.
    • Cancer. 2019 Nov 4. doi: 10.1002/cncr.32572. [Epub ahead of print]
    • Multigene Cancer Panels: Implications for Pre- and Post-test Genetic Counseling.
    • Grady MC, Kolla KA, Peshkin BN.
    • Curr Genet Med Rep. 2019 Nov 4. doi: 10.1007/s40142-019-00173-8. [Epub ahead of print]
    • Review
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.
    • [No author given]
    • National Institute for Health and Care Excellence (UK): Clinical Guidelines; 2013 Jun. [Last Update: November 2019.]
    • Determination of Pathogenicity of Breast Cancer 1 Gene Variants using the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines.
    • Brown A, Zamanpoor M, Love DR, Prosser DO.
    • Sultan Qaboos Univ Med J. 2019 Nov;19(4):e324-e334. doi: 10.18295/squmj.2019.19.04.008. Epub 2019 Dec 22.
    • FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers.
    • Ray T.
    • GenomeWeb. 2019 Oct 29.
    • New Consumer Podcast Highlights Steps Individuals Can Take to Understand Cancer Risk.
    • [No author given]
    • NSGC blog, 2019 Oct 29.

    Podcast: Genetic Counselors and You — Breast Cancer Awareness Month. (NSGC "Genetic Counselors & You" Podcast Series)

    • Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment.
    • Walker-Smith TL, Peck J.
    • Nurs Womens Health. 2019 Oct 25. pii: S1751-4851(19)30188-6. doi: 10.1016/j.nwh.2019.09.003. [Epub ahead of print]
    • Review
    • Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program.
    • Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A.
    • Hered Cancer Clin Pract. 2019 Oct 23;17:30. doi: 10.1186/s13053-019-0129-1.
    • Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management.
    • Tischler J, Crew KD, Chung WK.
    • Ann Intern Med. 2019 Oct 22. doi: 10.7326/M18-2417. [Epub ahead of print]
    • Review
    • Calling on Primary Care to Prevent BRCA-Related Cancers.
    • Armstrong K.
    • J Gen Intern Med. 2019 Oct 21. doi: 10.1007/s11606-019-05469-7. [Epub ahead of print]
    • Ellen Matloff's Forbes Article: What Beyoncé's Dad and Angelina Jolie Have in Common.
    • Matloff E.
    • My Gene Counsel. 2019 Oct 21.
    • Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
    • Scott D, Friedman S, Telli ML, Kurian AW.
    • J Oncol Pract. 2019 Oct 15:JOP1900221. doi: 10.1200/JOP.19.00221. [Epub ahead of print]
    • Population BRCA sequencing; time to move to the next phase?
    • Gourley C.
    • BJOG. 2019 Oct 12. doi: 10.1111/1471-0528.15984. [Epub ahead of print]
    • Commentary
    • Patterns and Predictors of Genetic Referral among Ovarian Cancer Patients at a National Cancer Institute Comprehensive Cancer Center.
    • Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Clin Genet. 2019 Oct 10. doi: 10.1111/cge.13654. [Epub ahead of print]
    • BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.
    • Capoluongo E, Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.
    • Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.
    • Adding RNA-Seq, Ambry Genetics Expects to Reduce VUS Results in Hereditary Cancer Tests.
    • [No author given]
    • GenomeWeb. 2019 Oct 4.
    • News
    • Genetic testing in ovarian cancer - clinical impact and current practices.
    • Knabben L, Imboden S, Mueller MD.
    • Horm Mol Biol Clin Investig. 2019 Oct 2. pii: /j/hmbci.ahead-of-print/hmbci-2019-0025/hmbci-2019-0025.xml. doi: 10.1515/hmbci-2019-0025. [Epub ahead of print]
    • Review
    • Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
    • Karam R, Conner B, LaDuca H, McGoldrick K, Krempely K, Richardson ME, Zimmermann H, Gutierrez S, Reineke P, Hoang L, Allen K, Yussuf A, Farber-Katz S, Rana HQ, Culver S, Lee J, Nashed S, Toppmeyer D, Collins D, Haynes G, Pesaran T, Dolinsky JS, Tippin Davis B, Elliott A, Chao E.
    • JAMA Netw Open. 2019 Oct 2;2(10):e1913900. doi: 10.1001/jamanetworkopen.2019.13900.

    Press: Ambry Genetics Study Finds RNA Testing Can Clarify Role of Variants in Hereditary Cancer Genes. (GenomeWeb)

    Press: Ambry Genetics Gains NYS Approval for Paired RNA, DNA Genetic Test. (GenomeWeb)

    • BRCA testing in unaffected young women in the United States, 2006-2017.
    • Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.
    • Cancer. 2019 Sep 30. doi: 10.1002/cncr.32536. [Epub ahead of print]
    • Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis.
    • Slavin TP, Sun CL, Chavarri-Guerra Y, Sedrak MS, Katheria V, Castillo D, Herzog J, Dale W, Hurria A, Weitzel JN.
    • J Geriatr Oncol. 2019 Sep 28. pii: S1879-4068(19)30174-2. doi: 10.1016/j.jgo.2019.09.004. [Epub ahead of print]
    • Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.
    • Sawyer L, Creswick H, Lewandowski R, Quillin J.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1173. [Epub ahead of print]
    • Patients' willingness to reconsider cancer genetic testing after initially declining: Mention it again.
    • Halverson CME, Wessinger BC, Clayton EW, Wiesner GL.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1174. [Epub ahead of print]
    • Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
    • Brédart A, Kop JL, Dick J, Cano A, De Pauw A, Anota A, Brunet J, Devilee P, Stoppa-Lyonnet D, Schmutzler R, Dolbeault S.
    • BMJ Open. 2019 Sep 24;9(9):e029926. doi: 10.1136/bmjopen-2019-029926.
    • Cancer Genetic Counseling—Current Practice and Future Challenges.
    • Schienda J, Stopfer J.
    • Cold Spring Harb Perspect Med. 2019 Sep 23. pii: a036541. doi: 10.1101/cshperspect.a036541. [Epub ahead of print]
    • Review
    • Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
    • Fragoso-Ontiveros V, Velázquez-Aragón JA, Nuñez-Martínez PM, de la Luz Mejía-Aguayo M, Vidal-Millán S, Pedroza-Torres A, Sánchez-Contreras Y, Ramírez-Otero MA, Muñiz-Mendoza R, Domínguez-Ortíz J, Wegman-Ostrosky T, Bargalló-Rocha JE, Gallardo-Rincón D, Reynoso-Noveron N, Arriaga-Canon C, Meneses-García A, Herrera-Montalvo LA, Alvarez-Gomez RM.
    • PLoS One. 2019 Sep 23;14(9):e0222709. doi: 10.1371/journal.pone.0222709. eCollection 2019.
    • Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    • Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM.
    • Breast Cancer Res. 2019 Sep 18;21(1):107. doi: 10.1186/s13058-019-1193-1.
    • Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
    • Ndugga-Kabuye MK, Issaka RB.
    • Fam Cancer. 2019 Sep 17. doi: 10.1007/s10689-019-00144-6. [Epub ahead of print]
    • A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
    • Li W, Li L, Wu M.
    • Hered Cancer Clin Pract. 2019 Sep 10;17:26. doi: 10.1186/s13053-019-0126-4. eCollection 2019.
    • [Guideline on next-generation sequencing-based BRCA1/2 testing (2019)].
    • Working Group of Guideline on Next-Generation Sequencing-Based BRCA1/2 Testing (2019).
    • Zhonghua Bing Li Xue Za Zhi. 2019 Sep 8;48(9):670-677. doi: 10.3760/cma.j.issn.0529-5807.2019.09.002.
    • Guidelines, [Article in Chinese]
    • Epigenetic Risk Assessment of Female Cancers: Women's Information Needs and Attitudes.
    • Rebitschek FG, Reisel D, Lein I, Wegwarth O.
    • Public Health Genomics. 2019 Sep 4;22(1-2):46-57. doi: 10.1159/000501975. [Epub ahead of print]
    • Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
    • Akter H, Sultana N, Martuza N, Siddiqua A, Dity NJ, Rahaman MA, Samara B, Sayeed A, Basiruzzaman M, Rahman MM, Rashidul Hoq M, Amin MR, Baqui MA, Woodbury-Smith M, Uddin KMF, Islam SS, Awwal R, Berdiev BK, Uddin M.
    • BMC Med Genet. 2019 Sep 2;20(1):150. doi: 10.1186/s12881-019-0881-0.
    • An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    • Piccinin C, Panchal S, Watkins N, Kim RH.
    • Expert Rev Anticancer Ther. 2019 Aug 30. doi: 10.1080/14737140.2019.1659730. [Epub ahead of print]
    • Review
    • The NCCN Criterion "Young Age at Onset" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population.
    • Ebrahimi E, Sellars E, Shirkoohi R, Harirchi I, Ghiasvand R, Mohebbi E, Zendehdel K, Akbari MR.
    • Cancer Prev Res (Phila). 2019 Aug 26. pii: canprevres.0056.2019. doi: 10.1158/1940-6207.CAPR-19-0056. [Epub ahead of print]
    • A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population.
    • Millan Catalan O, Campos-Parra AD, Vázquez-Romo R, Cantú de León D, Jacobo-Herrera N, Morales-González F, López-Camarillo C, Rodríguez-Dorantes M, López-Urrutia E, Pérez-Plasencia C.
    • Cancers (Basel). 2019 Aug 26;11(9). pii: E1246. doi: 10.3390/cancers11091246.
    • Universal Genetic Testing for All Breast Cancer Patients.
    • Copur MS.
    • Oncology (Williston Park). 2019 Aug 23;33(8). pii: 683731.
    • Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk.
    • Moreno-Conde J, Alvarez-Romero C, Suárez-Mejías C, Martínez-Maestre MÁ, Silvan-Alfaro JM, Parra-Calderón CL.
    • Stud Health Technol Inform. 2019 Aug 21;264:704-708. doi: 10.3233/SHTI190314.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    • Rajagopal PS, Nielsen S, Olopade OI.
    • JAMA Netw Open. 2019 Aug 20;2(8.10):e1910142. doi: 10.1001/jamanetworkopen.2019.10142.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • BRCA mutation in high grade epithelial ovarian cancers.
    • Manchana T, Phoolcharoen N, Tantbirojn P.
    • Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.
    • Who's on third? Regulation of third-party genetic interpretation services.
    • Guerrini CJ, Wagner JK, Nelson SC, Javitt GH, McGuire AL.
    • Genet Med. 2019 Aug 12. doi: 10.1038/s41436-019-0627-6. [Epub ahead of print]
    • Review
    • The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.
    • Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, Engel C, Wasem J, Neumann A.
    • Curr Med Res Opin. 2019 Aug 8:1. doi: 10.1080/03007995.2019.1654689. [Epub ahead of print]
    • Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
    • Rasnic R, Brandes N, Zuk O, Linial M.
    • BMC Cancer. 2019 Aug 7;19(1):783. doi: 10.1186/s12885-019-5994-5.
    • Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.
    • Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP.
    • Front Pharmacol. 2019 Aug 2;10:830. doi: 10.3389/fphar.2019.00830. eCollection 2019.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    • Moya-Alarcón C, González-Domínguez A, Simon S, Pérez-Román I, González-Martín A, Bayo-Lozano E, Sánchez-Heras AB.
    • Clin Transl Oncol. 2019 Aug;21(8):1076-1084. doi: 10.1007/s12094-018-02026-2. Epub 2019 Jan 8.
    • Strategies for Improving Access to Hereditary Cancer Testing: Recommendations from Stakeholders.
    • Ready K, Johansen Taber KA, Bonhomme N, Lichtenfeld JL.
    • Genet Med. 2019 Aug;21(8):1702-1704. doi: 10.1038/s41436-018-0430-9. Epub 2019 Jan 28.
    • Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    • Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.
    • J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.
    • The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients.
    • Bernstein-Molho R, Barnes-Kedar I, Ludman MD, Reznik G, Feldman HB, Samra NN, Eilat A, Peretz T, Peretz LP, Shapira T, Magal N, Kalis ML, Yerushalmi R, Vinkler C, Liberman S, Basel-Salmon L, Shohat M, Levy-Lahad E, Friedman E, Bazak L, Goldberg Y.
    • Breast Cancer Res Treat. 2019 Jul 31. doi: 10.1007/s10549-019-05379-6. [Epub ahead of print]
    • Targeted short read sequencing and assembly of re-arrangements and candidate gene loci provide megabase diplotypes.
    • Shin G, Greer SU, Xia LC, Lee H, Zhou J, Boles TC, Ji HP.
    • Nucleic Acids Res. 2019 Jul 27. pii: gkz661. doi: 10.1093/nar/gkz661. [Epub ahead of print]
    • New recurring BRCA1 variant: An additional South African founder mutation?
    • Gardiner SA, Smith D, Loubser F, Raimond P, Gerber J, Conradie M.
    • S Afr Med J. 2019 Jul 26;109(8):12676. doi: 10.7196/SAMJ.2019.v109i8.14187.
    • Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
    • Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07549-8. [Epub ahead of print]
    • Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    • Bashford MT, Kohlman W, Everett J, Parrott A, Pollin TI; Practice Guidelines Committee of the National Society of Genetic Counselors and the Professional Practice and Guidelines Committee of the American College of Medical Genetics and Genomics.
    • Genet Med. 2019 Jul 23. doi: 10.1038/s41436-019-0586-y. [Epub ahead of print]

    Guidelines:

    A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

    • Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.
    • Amendola LM, Hart MR, Bennett RL, Horike-Pyne M, Dorschner M, Shirts B, Jarvik GP.
    • J Genet Couns. 2019 Jul 17. doi: 10.1002/jgc4.1155. [Epub ahead of print]
    • Functional coding and non-coding variants in human BRCA1 gene and their use in genetic screening.
    • Tuncel G, Ergören MÇ.
    • Med Oncol. 2019 Jul 3;36(8):71. doi: 10.1007/s12032-019-1294-9.
    • Review
    • Adverse Events in Genetic Testing: The Fourth Case Series.
    • Farmer MB, Bonadies DC, Mahon SM, Baker MJ, Ghate SM, Munro C, Nagaraj CB, Besser AG, Bui K, Csuy CM, Kirkpatrick B, McCarty AJ, McQuaid SW, Sebastian J, Sternen DL, Walsh LK, Matloff ET.
    • Cancer J. 2019 Jul/Aug;25(4):231-236. doi: 10.1097/PPO.0000000000000391.
    • Case series
    • Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
    • Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK; International Society of Cancer Risk Assessment and Management.
    • Breast J. 2019 Jul;25(4):575-577. doi: 10.1111/tbj.13292.
    • Editorial
    • Germline genetics in localized prostate cancer.
    • Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK.
    • Curr Opin Urol. 2019 Jul;29(4):326-333. doi: 10.1097/MOU.0000000000000648.
    • Review
    • [Hereditary Breast and Ovarian Cancer Syndrome].
    • Inuzuka M, Nakamura S.
    • Gan To Kagaku Ryoho. 2019 Jul;46(7):1109-1113.
    • Review, [Article in Japanese]
    • The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.
    • Yim GW, Suh DH, Kim JW, Kim SC, Kim YT.
    • J Gynecol Oncol. 2019 Jul;30(4):e91. doi: 10.3802/jgo.2019.30.e91.
    • Multi gene panel testing for hereditary breast cancer - is it ready to be used?
    • Catana A, Apostu AP, Antemie RG.
    • Med Pharm Rep. 2019 Jul;92(3):220-225. doi: 10.15386/mpr-1083. Epub 2019 Jul 31.
    • A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer: The Emerging Role of Tumor and Germline Genetic Testing and the Treatment of Advanced Disease.
    • Srinivas S, Shah SA.
    • National Comprehensive Cancer Network. Continuing Education. 2019 Jun 24.
    • CME course
    • Current Genetic Service Delivery Models for the Provision of Genetic Testing in Europe: A Systematic Review of the Literature.
    • Unim B, Pitini E, Lagerberg T, Adamo G, De Vito C, Marzuillo C, Villari P.
    • Front Genet. 2019 Jun 19;10:552. doi: 10.3389/fgene.2019.00552. eCollection 2019.
    • Online Platform Helping Adventist Health Improve Breast Cancer Risk Assessment.
    • Versel N.
    • Precision Oncology News. Disease Areas. Cancer. 2019 Jun 7.
    • Press
    • Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
    • Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.
    • Public Health Genomics. 2019 Jun 4:1-11. doi: 10.1159/000499852. [Epub ahead of print]
    • [Risks of Solid Tumors in Heterozygous Carriers of Recessive Syndromes.]
    • Koudová M, Puchmajerová A.
    • Klin Onkol. 2019 Summer;32(Supplementum2):14-23. doi: 10.14735/amko2019S14.
    • A cost-effectiveness analysis of universal genetic testing for common hereditary cancer mutations in women compared with family-history based testing.
    • Drummey AB, Brown J, Drury L, Amacker-North L, Warsinske K, Tyrie K, Naumann RW.
    • Gynecol Oncol. 2019 Jun;153(3):e20. doi: 10.1016/j.ygyno.2019.03.152.
    • Conference abstract
    • Exploring genetic counselors' perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM).
    • Heinlen C, Hovick SR, Brock GN, Klamer BG, Toland AE, Senter L.
    • J Genet Couns. 2019 Jun;28(3):664-672. doi: 10.1002/jgc4.1079. Epub 2019 Mar 7.
    • Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?
    • Thomas MH, Higgs LK, Modesitt SC, Schroen AT, Ring KL, Dillon PM.
    • J Genet Couns. 2019 Jun;28(3):700-707. doi: 10.1002/jgc4.1044. Epub 2019 Feb 1.
    • Case report
    • Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
    • Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
    • Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
    • Hospital apologises to woman given wrong test result for breast cancer gene.
    • [No author given]
    • The Irish Times. 2019 May 29.
    • Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey.
    • Allen CG, Roberts M, Guan Y.
    • J Pers Med. 2019 May 10;9(2). pii: E26. doi: 10.3390/jpm9020026.
    • A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm.
    • Manchanda R, Gaba F.
    • BJOG. 2019 May;126(6):686-689. doi: 10.1111/1471-0528.15657.
    • Commentary
    • Identifying disparities in germline and somatic testing for ovarian cancer.
    • Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, George S.
    • Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. Epub 2019 Mar 16.
    • Non-BRCA1/2 Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer.
    • Adaniel C, Salinas F, Donaire JM, Bravo ME, Peralta O, Paredes H, Aliaga N, Sola A, Neira P, Behnke C, Rodriguez T, Torres S, Lopez F, Hurtado C.
    • J Glob Oncol. 2019 May;(5):1-14. doi: 10.1200/JGO.18.00163.
    • Women's perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study.
    • Rainey L, Jervaeus A, Donnelly LS, Evans DG, Hammarström M, Hall P, Wengström Y, Broeders MJM, van der Waal D.
    • Psychooncology. 2019 May;28(5):1056-1062. doi: 10.1002/pon.5051. Epub 2019 Mar 25.
    • Cases in Precision Medicine: When Patients Present With Direct-to-Consumer Genetic Test Results.
    • Artin MG, Stiles D, Kiryluk K, Chung WK.
    • Ann Intern Med. 2019 Apr 30. doi: 10.7326/M18-2356. [Epub ahead of print]
    • Case report
    • Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis.
    • Katki HA.
    • Stat Med. 2019 Apr 30. doi: 10.1002/sim.8163. [Epub ahead of print]
    • Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    • Zakrzewski F, Gieldon L, Rump A, Seifert M, Grützmann K, Krüger A, Loos S, Zeugner S, Hackmann K, Porrmann J, Wagner J, Kast K, Wimberger P, Baretton G, Schröck E, Aust D, Klink B.
    • BMC Cancer. 2019 Apr 27;19(1):396. doi: 10.1186/s12885-019-5584-6.
    • Scientific supremacy as an obstacle to establishing and sustaining interdisciplinary dialogue across knowledge paradigms in health medicine.
    • Gripsrud BH, Solbrække KN.
    • Med Health Care Philos. 2019 Apr 25. doi: 10.1007/s11019-019-09901-x. [Epub ahead of print]

    Commentary:

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    • Structural Aberrations with Secondary Implications (SASIs): consensus recommendations for reporting of cancer susceptibility genes identified during analysis of Copy Number Variants (CNVs).
    • Talukdar S, Hawkes L, Hanson H, Kulkarni A, Brady AF, McMullan DJ, Ahn JW, Woodward E, Turnbull C; UK Association for Clinical Genomic Science and UK Cancer Genetics Group.
    • J Med Genet. 2019 Apr 24. pii: jmedgenet-2018-105820. doi: 10.1136/jmedgenet-2018-105820. [Epub ahead of print]
    • Guidelines
    • "A natural progression" - Australian women's attitudes about an individualised breast screening model.
    • Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE.
    • Cancer Prev Res (Phila). 2019 Apr 19. pii: canprevres.0443.2018. doi: 10.1158/1940-6207.CAPR-18-0443. [Epub ahead of print]
    • Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
    • Peters MLB, Stobie L, Dudley B, Karloski E, Allen K, Speare V, Dolinsky JS, Tian Y, DeLeonardis K, Krejdovsky J, Button A, Lim C, Borazanci E, Brand R, Tung N.
    • Cancer. 2019 Apr 12. doi: 10.1002/cncr.32077. [Epub ahead of print]
    • Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
    • Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, Gabbouj S, Remadi Y, Hassen E, Bouaouina N, Zakhama A.
    • J Transl Med. 2019 Apr 11;17(1):123. doi: 10.1186/s12967-019-1873-8.
    • Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    • Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ.
    • J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854. [Epub ahead of print]

    Press: Genetic Testing Under-Utilized in Ovarian Cancer. (Medscape Oncology)

    • 23andMe DTC Breast and Ovarian Cancer Risk Test Misses Almost 90 Percent of BRCA Mutation Carriers.
    • Karow J.
    • Precision Oncology News. 2019 Apr 5.
    • Germline Genetic Testing: What the Breast Surgeon Needs to Know.
    • Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA, Hughes KS.
    • Ann Surg Oncol. 2019 Apr 2. doi: 10.1245/s10434-019-07341-8. [Epub ahead of print]
    • Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
    • Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, Krajc M, Skof E.
    • BMC Cancer. 2019 Apr 2;19(1):296. doi: 10.1186/s12885-019-5535-2.
    • Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals.
    • Bakhuizen JJ, Velthuizen ME, Stehouwer S, Bleiker EM, Ausems MG.
    • Fam Cancer. 2019 Apr;18(2):231-239. doi: 10.1007/s10689-018-0103-5.
    • Disparities in gynecologic cancer genetics evaluation.
    • Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2019 Apr;153(1):184-191. doi: 10.1016/j.ygyno.2019.01.024. Epub 2019 Jan 31.
    • Review
    • Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients.
    • Augusto B, Kasting ML, Couch FJ, Lindor NM, Vadaparampil ST.
    • J Immigr Minor Health. 2019 Apr;21(2):434-437. doi: 10.1007/s10903-018-0772-z.
    • Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
    • Feliubadaló L, López-Fernández A, Pineda M, Díez O, Del Valle J, Gutiérrez-Enríquez S, Teulé A, González S, Stjepanovic N, Salinas M, Capellá G, Brunet J, Lázaro C, Balmaña J; Catalan Hereditary Cancer Group.
    • Int J Cancer. 2019 Mar 29. doi: 10.1002/ijc.32304. [Epub ahead of print]
    • A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.
    • Forbes C, Fayter D, de Kock S, Quek RG.
    • Cancer Manag Res. 2019 Mar 22;11:2321-2337. doi: 10.2147/CMAR.S189627. eCollection 2019.
    • Ambry and My Gene Counsel Team Up on Tests to Confirm DTC Results, Counseling.
    • [No author given.]
    • Clinical OMICs. 2019 Mar 19.

    Original research:

    False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.

    • Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.
    • Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.
    • Clin Breast Cancer. 2019 Mar 11. pii: S1526-8209(18)30730-4. doi: 10.1016/j.clbc.2019.02.014. [Epub ahead of print]
    • RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Peshkin BN, Isaacs C, Schwartz MD.
    • J Natl Cancer Inst. 2019 Mar 5. pii: djz028. doi: 10.1093/jnci/djz028. [Epub ahead of print]

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    Original research:

    Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    • Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    • Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning AM, Decker B, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Borg Å, Grönberg H, Czene K.
    • Int J Cancer. 2019 Mar 1;144(5):1195-1204. doi: 10.1002/ijc.31841. Epub 2018 Nov 9.
    • BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
    • Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI.
    • Asia Pac J Clin Oncol. 2019 Mar;15 Suppl 2:20-31. doi: 10.1111/ajco.13116. Epub 2019 Mar 6.
    • Genetic testing and insurance in Australia.
    • Otlowski M, Barlow-Stewart K, Lacaze P, Tiller J.
    • Aust J Gen Pract. 2019 Mar;48(3):96-99.
    • Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".
    • Narod SA.
    • Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.
    • Letter, Reply

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Review:

    Personalised medicine and population health: breast and ovarian cancer.

    • Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    • Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K.
    • Eur J Health Econ. 2019 Feb 21. doi: 10.1007/s10198-019-01038-1. [Epub ahead of print]
    • Psychosocial, attitudinal, and demographic correlates of cancer-related germline genetic testing in the 2017 Health Information National Trends Survey.
    • Roberts MC, Turbitt E, Klein WMP.
    • J Community Genet. 2019 Feb 20. doi: 10.1007/s12687-018-00405-4. [Epub ahead of print]
    • Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.
    • Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P.
    • Genet Med. 2019 Feb 18. doi: 10.1038/s41436-019-0457-6. [Epub ahead of print]
    • Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
    • Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ.
    • J Natl Cancer Inst. 2019 Feb 8. doi: 10.1093/jnci/djz008. [Epub ahead of print]

    Editorial:

    Persistent underutilization of BRCA1/2 testing suggest the need for new approaches to genetic testing delivery.

    • Genetic Service Delivery Models: Exploring Approaches to Care for Families With Hereditary Cancer Risk.
    • Pierle JM, Mahon SM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):60-67. doi: 10.1188/19.CJON.60-67.
    • The impact of variant classification on the clinical management of hereditary cancer syndromes.
    • Turner SA, Rao SK, Morgan RH, Vnencak-Jones CL, Wiesner GL.
    • Genet Med. 2019 Feb;21(2):426-430. doi: 10.1038/s41436-018-0063-z. Epub 2018 Jun 6.
    • [Hereditary predisposition to breast cancer (1): genetics].
    • Cohen-Haguenauer O.
    • Med Sci (Paris). 2019 Feb;35(2):138-151. doi: 10.1051/medsci/2019003. Epub 2019 Feb 18.
    • Guidelines-Based Cancer Risk Assessment.
    • Forman A, Schwartz S.
    • Semin Oncol Nurs. 2019 Feb;35(1):34-46. doi: 10.1016/j.soncn.2018.12.010. Epub 2019 Jan 22.
    • Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Ohmoto A, Yachida S, Morizane C.
    • Int J Mol Sci. 2019 Jan 29;20(3). pii: E561. doi: 10.3390/ijms20030561.
    • A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.
    • Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.
    • Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS).
    • Ramírez-Calvo M, García-Casado Z, Fernández-Serra A, de Juan I, Palanca S, Oltra S, Soto JL, Castillejo A, Barbera VM, Juan-Fita MJ, Segura Á, Chirivella I, Sánchez AB, Tena I, Chaparro C, Salas D, López-Guerrero JA.
    • Hered Cancer Clin Pract. 2019 Jan 18;17:3. doi: 10.1186/s13053-019-0104-x. eCollection 2019.
    • Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
    • Autier P.
    • JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6501. [Epub ahead of print]
    • Letter, Comment

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply.

    Original research:

    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

    • Food and drug administration's regulatory shift on direct-to-consumer genetic tests for cancer risk.
    • Yang YT, Zettler PJ.
    • Cancer. 2019 Jan 1;125(1):12-14. doi: 10.1002/cncr.31773. Epub 2018 Nov 2.
    • Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.
    • J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.

    Letter, comment:

    RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    • Molecular Testing in Breast Cancer.
    • Litton JK, Burstein HJ, Turner NC.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):e1-e7. doi: 10.1200/EDBK_237715.
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • BRCA mutations: is everything said?
    • López-Urrutia E, Salazar-Rojas V, Brito-Elías L, Coca-González M, Silva-García J, Sánchez-Marín D, Campos-Parra AD, Pérez-Plasencia C.
    • Breast Cancer Res Treat. 2019 Jan;173(1):49-54. doi: 10.1007/s10549-018-4986-5. Epub 2018 Oct 6.
    • Review
    • European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.
    • Rutgers E, Balmana J, Beishon M, Benn K, Evans DG, Mansel R, Pharoah P, Perry Skinner V, Stoppa-Lyonnet D, Travado L, Wyld L.
    • Eur J Cancer. 2019 Jan;106:45-53. doi: 10.1016/j.ejca.2018.09.019. Epub 2018 Nov 22.
    • Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
    • Singer CF, Balmaña J, Bürki N, Delaloge S, Filieri ME, Gerdes AM, Grindedal EM, Han S, Johansson O, Kaufman B, Krajc M, Loman N, Olah E, Paluch-Shimon S, Plavetic ND, Pohlodek K, Rhiem K, Teixeira M, Evans DG.
    • Eur J Cancer. 2019 Jan;106:54-60. doi: 10.1016/j.ejca.2018.10.007. Epub 2018 Nov 22.
    • Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review.
    • Yanes T, Willis AM, Meiser B, Tucker KM, Best M.
    • Eur J Hum Genet. 2019 Jan;27(1):28-35. doi: 10.1038/s41431-018-0257-5. Epub 2018 Sep 11.
    • Review
    • Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant.
    • De Bonis M, Minucci A, Scaglione GL, De Paolis E, Zannoni G, Scambia G, Capoluongo E.
    • Fam Cancer. 2019 Jan;18(1):29-35. doi: 10.1007/s10689-018-0094-2.
    • Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations.
    • Grimmett C, Brooks C, Recio-Saucedo A, Armstrong A, Cutress RI, Gareth Evans D, Copson E, Turner L, Meiser B, Wakefield CE, Eccles D, Foster C.
    • Support Care Cancer. 2019 Jan;27(1):297-309. doi: 10.1007/s00520-018-4307-x. Epub 2018 Jun 28.

Continue to Older References